

Definition and Measurement of Follicle Stimulating Hormone

MATTHEW P. ROSE, ROSE E. GAINES DAS, AND ADAM H. BALEN

Division of Endocrinology (M.P.R.) and Informatics Laboratory (R.E.G.D.), National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire EN6 3QG; and The General Infirmary at Leeds (A.H.B.), United Leeds Teaching Hospitals National Health Service Trust, Belmont Grove, Leeds, West Yorkshire LS2 9NS, United Kingdom

ABSTRACT

FSH has a key role in the development and function of the reproductive system and is widely used both diagnostically and therapeutically in developmental and reproductive medicine. The accurate measurement of FSH levels, in patients for diagnosis and monitoring and in therapeutic preparations for clinical use, is essential for safe and successful treatment. Historically, FSH was defined on the basis of classical *in vivo* endocrine activity, and early therapeutic preparations were calibrated using *in vivo* bioassays. There was early recognition that reference preparations were required for calibration if the results from different laboratories were to be comparable. In

response to the perceived need, the World Health Organization established the first standard for such preparations in 1959. Subsequent developments in biotechnology have led to recognition that there is no single molecule that can be uniquely defined as FSH, and that FSH can induce a range of biological activities. Several highly purified standards for FSH are now available, but discontinuity and heterogeneity of estimates of FSH activity in terms of these standards made using *in vitro* assays and binding assays have been noted. It is thus essential that any measurement of FSH include specification both of the standard with which the measured FSH is compared and the assay method used for that comparison. (*Endocrine Reviews* 21: 5–22, 2000)

- I. Introduction
- II. Clinical Importance of FSH
 - A. Therapeutic uses
 - B. Diagnostic use
- III. Definition of FSH
- IV. Function of FSH
 - A. Structure/function relationships
 - B. Relationship of FSH structure to physiology
 - C. Biological clearance
- V. Metrological Considerations and the Need for Standards
 - A. Standards for FSH
 - B. Future Prospects for FSH Standards
- VI. Assay Systems Used for Measurement of FSH
 - A. Bioassays
 - B. High-affinity binding assays
 - C. Physicochemical assays
- VII. Interpretation of FSH Measurements
 - A. Effect of different isoforms in different assay systems
 - B. Effect of different forms of FSH on FSH determinations
- VIII. Conclusions

I. Introduction

FSH is a member of the glycoprotein hormone family that has a central and essential role in reproduction. FSH determination is fundamental to elucidating reproductive

physiology, regulating fertility, and diagnosing and treating disorders of reproduction. FSH exists in many different molecular forms, which may have different reactivities both in physiological systems and in different assay types. Thus FSH is not a single entity but is a heterogeneous population of different forms, which changes under different physiological and pathological situations. Moreover, FSH exerts a number of biological effects that have served as the basis for the different types of assay that have been developed for its estimation. Use of a particular assay depends upon the purpose for which the measurement is being made, the nature of the sample that is being analyzed, and the availability of different assay types. Thus, the “true” estimation of FSH, each form of which may react differently in the different assay systems used for estimation, is an ideal that will not be readily achieved.

This review considers how FSH is defined either in terms of its biological activity or in molecular terms, summarizes the different assay formats developed for its determination, and describes how the properties of FSH may influence its determination and hence the conclusions that are drawn from such determinations. Although many of the principles that apply to FSH apply to all members of the glycoprotein hormone family (*i.e.*, FSH, TSH, LH, and CG) and to other clinically important glycoproteins such as erythropoietin, there have been particular problems associated with setting up international standards for calibration of FSH assays.

II. Clinical Importance of FSH

A. Therapeutic uses

Preparations derived from human menopausal urine [menotrophin, human menopausal gonadotropin (hMG)]

Address reprint requests to: Matthew P. Rose, Ph.D., Rademacher Group Limited, 2nd Floor Florey House, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, United Kingdom. E-mail: Matthew.Rose@Rademacher.co.uk

and containing FSH have been in clinical use since the 1960s (for historical review see Ref. 1). Advances in biotechnology have enabled industrial production of therapeutic grade urinary FSH (urofollitropin) and recombinant DNA (rDNA)-derived human FSH with high specific activity and minimal contamination by non-FSH materials. The properties of hMG and urofollitropin are defined by pharmacopeial monographs (*e.g.*, Ref. 2), as are the requirements of the (*in vivo*) bioassays used to test their potency.

Therapeutic preparations of FSH are widely used in the treatment of infertility (Table 1). The principles and practices for the gonadotrophic manipulation of the human ovary have been reviewed (3). Their use in assisted reproduction technology can be divided into three categories:

1. Induction of ovulation when a single healthy oocyte is required.
2. Induction of multiple ovulation or superovulation to maximize efficiency when assisted reproductive technologies are used that allow replacement of a fixed number of embryos.
3. Stimulation of spermatogenesis.

Treatment of female infertility is a situation in which patients are otherwise generally healthy and common disorders of reproduction such as anovulatory infertility can be treated in a safe and effective way (4). However, there is a narrow dose-range for use of FSH between a threshold level required to stimulate growth of a follicle(s) and the maximal dose (ceiling) above which overstimulation can occur (5). Thus there is a significant risk to health due to the iatrogenic induction of ovarian hyperstimulation syndrome or multiple pregnancies. Different physiological and clinical states can affect the levels of the threshold and ceiling for FSH treatment. Thus careful dose adjustment and monitoring of FSH levels and ovarian responses are required, particularly for patients with polycystic ovary syndrome (*e.g.*, Ref. 6). This cannot be achieved without accurate and reproducible calibration of therapeutic products. However, the end point used for patient response to therapeutic preparations should also be carefully considered.

B. Diagnostic use

The measurement of FSH in the circulation is widely employed in the diagnosis of disorders of reproduction and

development (Table 2). In general, immunoassays are used for these measurements because of their practical advantages. A disadvantage is that immunoassays may not provide information about the biological activity of the FSH measured, although this may be less relevant in routine clinical management than in detailed studies.

The primary use of FSH measurements is for assessment of gonadal function. Through classical endocrine feedback pathways, an elevated level of FSH indicates reduced gonadal function or gonadal failure, whereas a normal serum concentration of FSH suggests normal gonadal function. A low serum FSH may indicate a problem at the level of the hypothalamus or pituitary.

A measurement of serum FSH, with measurement of LH and either estradiol or testosterone, may be helpful in children with suspected premature puberty or in cases of delayed puberty, particularly as the application of sensitive assay methodologies permits detection of hormonal changes before clinical changes of puberty are observed (7). FSH measurement is indicated in men with azoospermia or severe oligospermia to help determine the degree to which the problem is due to gonadal failure (8).

Ovarian reserve, or the total number of remaining oocytes within the ovary, declines with ovarian age, but this does not always equate with the age of the woman. A baseline measurement of serum FSH concentration, usually on day 3 of the menstrual cycle, is a fairly good predictor of ovarian reserve in women of reproductive years (9). A fluctuating baseline FSH level is indicative of compromised ovarian function. The picture is further enhanced if measurement of FSH is combined with serum estradiol and inhibin (reviewed in Ref. 10). In an irregular menstrual cycle it can be difficult to time collection of samples correctly, and therefore more than one sample may have to be taken, often in combination with an ultrasound scan of the ovaries, to help determine the stage in the cycle (11–14). Measurement of FSH is also helpful in determining the presence of common disorders of reproduction such as polycystic ovary syndrome, when classically the serum LH concentration is elevated, while FSH is usually normal (15). A single measurement of FSH is not predictive of the timing of menopause and is not usually recommended for this purpose, although it may be useful in developing a differential diagnosis to exclude other causes (endocarditis

TABLE 1. Common causes of infertility and treatments that require FSH

Cause	Treatment
Female infertility	
Ovulatory failure (oligo- or amenorrhea)	Ovulation induction
Primary ovarian failure	Superovulation followed by IVF using donated oocytes
Tubal/pelvic damage ^a	Superovulation and IVF
Endometriosis ^a	Superovulation and IVF, GIFT, IUI
Cervical mucus dysfunction or defects	Superovulation and IUI, GIFT, IVF, ZIFT
Antisperm antibodies	Superovulation and IVF, IUI
Idiopathic infertility	Superovulation and IVF, GIFT, IUI
Male infertility	
Sperm dysfunction	IVF, ICSI
Azoospermia	Stimulation of spermatogenesis with FSH if due to hypogonadotropic hypogonadism or pituitary failure

Abbreviations: IVF, *In vitro* fertilization; GIFT, Gamete intra-fallopian tube transfer; IUI, Intra-uterine insemination; ICSI, Intra-cytoplasmic sperm injection; ZIFT, Zygote intra-fallopian tube transfer.

^a May be treated surgically in appropriate cases.

TABLE 2. Summary of clinical situations where FSH determinations are useful or are commonly requested

Clinical condition	Comments
Anovulatory infertility (oligo/amenorrhea)	To help determine whether cause is pituitary or gonadal in origin and to aid diagnosis of conditions such as polycystic ovary syndrome
Suspected premature puberty	In addition to steroid hormone levels
Delayed puberty	In addition to steroid hormone levels
Azoospermia/severe oligospermia	To differentiate pituitary and gonadal causes
Ovarian reserve	As a biological marker for the number of releasable oocytes; may be enhanced by measurements of inhibin and ovarian ultrasound to accurately stage the timing of the sample
Menopausal status	A frequently requested test; FSH is not a good marker for timing of the menopause or of perimenopausal state

or pheochromocytoma for example) of symptoms such as hot flushes. Although various studies have been performed to characterize the perimenopausal status (16, 17), the practical use of FSH measurement is in the prediction of ovarian response to stimulation in the context of assisted reproduction.

Significant between-assay heterogeneity is observable for FSH assays. However, it is not clear whether this may have a significant effect on diagnoses based on results obtained from different assay systems. In the United Kingdom a large clinical chemistry laboratory may perform several thousand FSH assays per year. The majority will be for investigations of menopausal status, diagnoses of infertility/amenorrhea, and infertility in men (see above). Essentially, the clinician will wish to detect gross changes in FSH levels from the normal ranges, and it is unlikely that variations between assays will mask gross changes in FSH concentration associated with primary gonadal failure and hypogonadotropic hypogonadism. The change to more acidic forms of FSH at menopause may be an example of a qualitative assay providing diagnostically useful information since a change in isoform composition may precede the observed increase in levels of FSH associated with the menopause. The levels of FSH measured by immunoassay at this time could also be affected by a change in isoform profile relating to the selectivity of the assay system used. However, in some circumstances, minor variations between assays could have a more profound effect, *e.g.*, partial gonadal failure/resistant ovary syndrome. Intensive investigations of hormonal levels have revealed underlying gonadotropin disturbances and imbalances in polycystic ovary syndrome (18) and subtle changes relating to idiopathic infertility (19). The ratio of LH to FSH has been proposed as a good predictor of ovarian hyperstimulation syndrome (20). In such cases, particularly where a ratio of two measurements is made, it is important to maintain continuity of unitage between estimates derived from different assays over a period of time and thus from one standard preparation to the next.

III. Definition of FSH

The history of the elucidation of FSH has been briefly reviewed (21). The salient features are that gonadotropins, or gonadotrophic principles as they were originally described, were first identified and defined in terms of their biological activities and that the assays developed for gonadotropins were based on classical endocrine principles. These early

assays had two main drawbacks (21). First, there was no assay specific for FSH, and second, quantification and hence between-laboratory comparisons were made difficult by a lack of standardization. Thus, the early assays measured a number of different biological responses to the different gonadotrophic principles and, furthermore, the extracts which defined gonadotrophic activity were composed of mixtures of the gonadotrophic principles.

After further scientific progress the structure of the glycoproteins for a variety of species in terms of amino acid sequence (22–29), carbohydrate composition (30–33), and gene sequences (*e.g.*, Refs. 34–36) have been determined and extensively reviewed (37–42). Human FSH can be defined in molecular terms as a heterodimeric glycoprotein hormone consisting of two noncovalently linked subunits designated α and β , which consist of 92 amino acids and 111 amino acids, respectively, and which are products of different genes. Each subunit has two N-linked glycosylation sites, which are on Asn 52 and Asn 78 for the α -subunit and Asn 7 and Asn 24 for the β -subunit and which are essential for expression of FSH bioactivity.

IV. Function of FSH

The biological actions of FSH can be summarized as follows; in the male, FSH, in combination with testosterone (which is under the control of LH), is required for the initiation and maintenance of qualitatively and quantitatively normal spermatogenesis (reviewed in Ref. 43). Although recent data in transgenic mice suggest that FSH appears to be not essential for male fertility (44), spermatogenesis is not completely normal in the absence of FSH and, furthermore, the requirement for FSH is more critical in primates than in rodents.

In the female FSH is necessary for the selection and growth of ovarian follicles and for the production of estrogens from androgen substrates. The gonadotrophic effects of FSH may be subserved by a number of intermediaries (reviewed in Ref. 45) that form part of the cellular and tissue (*e.g.*, Ref. 46) response to FSH stimulation culminating in ovulation. Such cellular responses illustrate the complex nature of FSH since they indicate that FSH activity has many components, *i.e.*, FSH is a growth factor or tropic hormone, a secretagogue, and a modulator of cellular development (*e.g.*, Ref. 47). It is generally thought that FSH exerts most of its intracellular actions via the cAMP-mediated signaling pathway, although

FSH may also utilize other signal transduction pathways such as Ca^{++} (48).

The biological activity of FSH is the sum of a complex combination of processes: release from the pituitary, survival in the circulation, transport to the site of action (*i.e.*, the gonad), binding to the receptor, and activation of signal transduction pathways. These processes may be modified by other factors that may affect release (pulse frequency or amplitude), clearance from the circulation, receptor binding and desensitization, cellular responsiveness, and modifications to the hormone during circulation such as neuraminidase action.

A. Structure/function relationships

1. *Amino acid sequence.* The α - and β -subunits of the gonadotropins are noncovalently linked but their individual conformations are determined by intramolecular disulfide bonds. Recently, glycoprotein hormones have been identified as members of the cysteine knot family of growth factors (49, 50). The disulfide bonds of the cysteine knot of the α -subunit have been found to be critical for heterodimer formation and/or secretion (51, 52), and conformational changes that occur in association with different hormone-specific β -subunits are assumed therefore to occur outside this essential core region of the α -subunit molecule.

The amino acid sequence $^{48}\text{QKTCT}^{52}$ of the β -subunit appears to be essential for formation of the FSH heterodimer (53), and the disulfide bonds 7–31 and 59–87 are important for heterodimer formation of LH but not of human (h)CG and hFSH (54). Further studies showed that the residues Phe³³, Arg³⁵ and Arg⁴²-Ser⁴³-Lys⁴⁴ are essential for receptor binding of hCG and hTSH but not for hFSH (55), whereas His⁹⁰-Lys⁹¹ of the α -subunit is essential for binding of FSH to its receptor but not for binding of hCG to the LH/hCG receptor (56, 57). Interestingly, this sequence is required for stimulation of cAMP by both hormones. Receptor binding sites have been identified within the 93–99 amino acid sequence of the C-terminal region of the FSH β -subunit (58). In the hCG α -subunit the sequence between amino acids 33–45 contains several residues that are essential for binding to the β -subunit and some of which are involved in receptor binding (59). The hormonal specificity of each subunit is thought to reside in a determinant loop formed between residues Cys 93 and Cys 100 of CG β -subunit and the equivalent sequences of the other β -subunits (60). This loop has been shown to form a seat belt around the α -subunit in the heterodimer (49, 50).

2. *Oligosaccharides.* The functions of the oligosaccharides have been investigated in two main ways. Earlier studies made use of chemical (61–63) or enzymatic alterations (64, 65) to the glycan moieties. The enzymatic approach allows investigation of the function of each sugar in the glycan by using sequential exoglycosidases to expose each sugar in turn (66), whereas chemical methods rapidly remove key sugar groups leaving a core structure intact. One possible drawback of chemical methods is that the treatment may alter the polypeptide chain in some way. More recently, molecular biology techniques have been used to produce molecules that were not glycosylated at individual sites by induction of

mutations in the polypeptide backbone, which prevent glycosylation (67). Site-directed mutagenesis has the advantage of permitting investigation of the role of individual glycosylation sites but also has the effect of removing the entire glycan structure and does not therefore allow investigation of the effect of sugar heterogeneity at any one site. A combination of site-directed mutagenesis and enzymatic or chemical modification may address this issue. The available evidence suggests that the protein structure was similar in intact and chemically treated preparations (62) and that the thermal stability of chemically deglycosylated hCG may be enhanced compared with the native hormone (68).

Hormones with deglycosylated α -subunit are antagonists of the action of intact hormones. Oligosaccharides on the α -subunit are required for signal transduction, in particular $\alpha 52$ (69), intracellular stability, and association with the β -subunit (70). Those on the β -subunit are required for β -subunit folding (71, 72) and for correct disulfide bond formation (73).

Although substantial work has been done, the complexities of the situation arising from variations of glycosyl content at each of the four possible glycosylation sites and the interactions of these structural features with biological systems are still incompletely understood.

B. Relationship of FSH structure to physiology

FSH is heterogeneous and the pattern of FSH forms changes with different physiological situations (reviewed in Refs. 74 and 75). Variability in the sugar chains is the major cause of heterogeneity in the gonadotropins, although microheterogeneity exists in the polypeptide chain.

An overall change in FSH isoform pattern resulting in a more basic composition has been observed in the middle of the menstrual cycle (76), in response to a GnRH challenge during puberty (77, 78), and in girls and young women compared with boys and men (79). In women, more acidic forms of FSH appear after the menopause (79, 80), the longer half-life of which may contribute to the increased serum FSH concentrations observed.

The profile of observed isoforms has also been shown to change with various hormonal treatments in humans and experimental animals and cultured rat pituitary cells (*e.g.*, Ref. 81). The changing patterns of isoforms observed under different conditions in humans (79–85) and other species (86–88) have been described. These data strongly implicate a role for sex steroids in controlling the isoform profile of FSH in women; in contrast, in men (82) and male rats (87) the evidence for androgens exerting the same effect is not as strong, and other factors such as inhibin are also implicated in controlling both the isoform profile and the amount of FSH secreted. The association of particular isoform patterns or molecular forms of FSH to particular actions or cellular and physiological responses is difficult to make because of the pleiotropic actions of FSH and the complexity of its molecular structure.

C. Biological clearance

Data from *in vivo* bioassays suggest that one of the major factors that controls FSH action is the relative rate of clear-

ance of different isoforms. The main mechanism of clearance of glycoproteins appears to be the hepatic route (89) or the renal route (90).

1. *Hepatic clearance.* Terminal sialic acid and sulfate groups are important for regulating biological half-life of glycoproteins (91). Subterminal galactose residues are recognized by the hepatic asialoglycoprotein receptor (92), and a sulfated glycoprotein receptor (93) is responsible for rapid clearance of sulfated glycoprotein hormones such as LH and TSH (94, 95). It is likely that molecules with a low sialic acid content but whose sugar structures are recognized by the asialoglycoprotein receptor may be cleared by this mechanism although hCG does not appear to be desialylated *in vivo* to render it a substrate for hepatic clearance (96).

Cellular uptake of asialoglycoproteins can be investigated *in vitro* by use of cultured liver cells or cell lines (97–99). There are, however, differences in the uptake of asialoglycoproteins by liver cells from different species (98) and between hormone molecules of natural or synthetic origin (95). These differences could contribute to differences in potency observed between natural and recombinant molecules (95) and in different situations (*e.g.*, pharmacopeial *in vivo* bioassay *vs.* clinical use of therapeutic preparations). With further development this model might be used to assess hepatic clearance when estimating FSH activity in serum or in therapeutic products *in vitro*.

2. *Renal clearance.* The renal route results in excretion of biologically active gonadotropins in the urine (100) or in degradation (90). Radiolabeled FSH and deglycosylated FSH (which is cleared from the circulation faster than intact FSH) appear to be cleared largely through the renal route rather than the hepatic route (101). Excretion may occur after filtration, which may be regulated by the surface charge and relative molecular size of the molecule (102). The loss of negative charge caused by removal of terminal sialic acids may therefore enhance renal filtration of desialylated molecules. Cellular uptake and degradation (90) may also be influenced by surface charge or by recognition by cell surface receptors or may require a cellular uptake mechanism that could be mediated by a mechanism similar to the transendothelial trafficking described previously (103). There is good evidence that the β -core of hCG is produced during elimination of the hCG molecule through the kidney (104). It would be difficult to model the renal route and to include models of both renal and hepatic routes of biological clearance into routine *in vitro* assays.

V. Metrological Considerations and the Need for Standards

The process of discovering that a property is “measurable” and setting up a procedure for measuring it depends entirely upon experimental inquiry, and is an important part of experimental science (105). More specifically, measurement of a quantity consists of ascertaining its ratio to another fixed quantity of the same kind, known as the “unit” of that quantity. Any unit is an abstract concept and cannot be used as a basis of measurement until it has been defined in one of two

ways: by reference to an arbitrary material standard, or by reference to a natural phenomenon. Thus, an essential requirement for any meaningful measurement is definition of the “quantity” being measured, of the “units” in which it is measured, and of the process by which the measurement is carried out. The need for metrological definition in the context of assays has been discussed both generally (106, 107) and in the context of specific types of assay (108, 109). Failure to define clearly what is meant by “measurement” of FSH (or of hormones more generally) can be the source of ambiguity and apparent inconsistencies.

The main assumption underlying a valid determination of any measurement is that the quantity to be measured and the standard with which it is compared are “of the same kind”. This requirement and its implications for bioassays have been extensively discussed (110–113). Although FSH was initially defined in terms of its ability to produce specific biological effects, it is now known both that materials with different molecular structures can produce these effects, and that there is no unique molecule that can be defined as FSH (Sections III and IV). Thus, definition of the “quantity to be measured” and provision of a sample “of the same kind” are not simple. In certain cases, the ability to produce specific effects in a biological system may still serve as the basis for definition of FSH. Biological responses, while they may be used to provide a definition of FSH, are not capable of defining the “units” of FSH, or indeed of any other hormone, as was recognized early in the study of such materials (114). Nevertheless, biological responses may serve as the basis of a measuring system for “FSH” in the form of bioassays.

The structure of an assay involves a subject (*e.g.*, an animal or a cell culture in the case of a bioassay, or an antibody-coated well of a microtiter plate in the case of an immunoassay) that responds in some measurable way to an application of a defined amount of the hormone. The relationship between the response and the amount or dose of hormone (the dose-response relationship) will be subject to random variations arising from the variations between replicate subjects. The availability of a material standard of the hormone with a defined unitage permits the application of “known” amounts of the standard to an array of subjects, while defined amounts of the substance to be measured are applied to a similar array of subjects. Subject to certain assumptions about validity, the comparison of the dose-response relationships for the standard and the unknown to be measured then gives a value of the FSH unitage to the substance being measured (110, 113).

Measurements of FSH are required for a variety of reasons (Section II). The definition of “FSH,” its measurable property (*e.g.*, biological activity), and the corresponding measurement process (*e.g.*, bioassay) must be related to the purpose for which the measurement is required.

One of the more important requirements for measurement of FSH is to determine the potency of therapeutic products. For this purpose, the quantity to be measured is the product, which may be defined by its production process and various physical or chemical specifications. The property to be measured is the capability of this quantity of material to produce a biological effect in patients. The units in terms of which this property is measured are International Units defined by ref-

erence to the International Standard, a material reference, and the measurement process is a pharmacopeially defined *in vivo* bioassay (Section VI.A).

"Measurements of FSH" are also made for samples of biological fluids from patients. The measuring system most commonly used is an immunoassay, in which case the property being measured is the binding of particular molecular forms. However, the molecular forms bound are seldom well defined (Section VI.B).

A. Standards for FSH

The First International Reference Preparation (IRP) of hMG was established in 1959, in response to a request by the International Federation of Gynaecology and Obstetrics, with no defined unitage, and was described as "ampoules containing 22 mg of dried active principle from urine of post-menopausal women" (115). This early preparation was found to be toxic in some assays, and a second preparation was evaluated by international collaborative study and became the second IRP (116). Subsequently, international standards for hMGs were established by the World Health Organization (WHO) and were calibrated by bioassay in terms of the second IRP (117). IRPs derived from pituitary extracts were also calibrated by bioassay in terms of the second IRP for menopausal gonadotropins. The unitage of biological activity assigned to the second IRP has served as the basis for definition of FSH activity of all subsequent WHO international standards and reference preparations (Table 3). The principles, use, and availability of standards for gonadotropins have been reviewed (118, 119) and have been recently updated (120).

These standards have been of service to the scientific and medical communities, although some problems have been noted. The change from use of relatively impure preparations to use of purified preparations as therapeutic products was followed by some studies indicating that on a unit-for-unit basis recombinant preparations appeared to be more

potent clinically than their urinary counterparts (121), although such findings were not universal (*e.g.*, Ref. 122). Thus, international standards of the purified preparations have been prepared and calibrated (123), and at present therapeutic preparations of gonadotropins are calibrated in terms of the appropriate international standard (Table 3) using the pharmacopeial *in vivo* bioassay.

There is at present no single standard that may be considered appropriate for general use in *in vitro* bioassays and immunoassays. Although some of the international standards have been used for these assays and may help to decrease interassay variation (124), significant interassay heterogeneity of estimates has been observed in two international collaborative studies (123, 125, 126). Furthermore, different international standards have been found to have different molecular compositions (127, 128) demonstrating the difficulty of preparing candidate standard materials from natural sources with reproducible properties. The possibility of standardization of the assay systems has been considered (124, 129–132). However, the difficulties inherent in standardization of bioassays have long been recognized (111), and similar considerations apply to immunoassays.

B. Future prospects for FSH standards

Further developments arising from the application of biotechnology may lead to the generation of purified preparations of defined but differing isoform composition or new molecules with therapeutic potential (133–135), which may require new assays and new standard preparations for their calibration. High purity preparations can be analyzed using physicochemical techniques that were not applicable to hMG preparations. At present, however, therapeutic materials, including those derived from rDNA sources, are calibrated by *in vivo* bioassay (see Section VI.A).

If immunoassay or lectin-antibody systems can be developed that select for certain forms of FSH such as acidic forms, then it may be appropriate to prepare standards of differing

TABLE 3. World Health Organization International Reference Preparations (IRP) and International Standards (IS) for FSH

Preparation	Code	Source	Calibration	
			Potency (IU FSH/ampoule) ^a	Standard
1st IRP for menotrophins ^b	hMG 24	Dried active principle from urine of postmenopausal women	22 mg	N.A.
2nd IRP for menotrophins ^b		Pergonal 23	40 (by definition)	1st IRP for menotrophins
1st IS for menotrophins ^b	70/45	Pergonal batch P49 E229C	54	2nd IRP for menotrophins
2nd IS for menotrophins ^b	71/223	Pergonal batch P49 E229C	54	2nd IRP for menotrophins
3rd IS for menotrophins ^b	71/264	Pergonal batch P49 E229C	54	2nd IRP for menotrophins
1st IS for urofollitropin	92/512	Urofollitropin	121	2nd IS for menotrophins
1st IS for rDNA-derived hFSH	92/642	RDNA-derived hFSH	138	2nd IS for menotrophins
1st IRP for FSH and LH pituitary ^b	69/104	Pituitary extract FSH/LH LER 907	10	2nd IRP for menotrophins
2nd IRP for FSH and LH pituitary ^b	78/549	Pituitary FSH/LH LER 907	10	1st IRP for FSH and LH pituitary
Interim reference preparation	94/632	Pituitary FSH/LH LER 907	20	2nd IRP for FSH and LH pituitary
1st IS for FSH, human pituitary	83/575	Highly purified pituitary FSH	80	2nd IRP for FSH and LH pituitary
1st IS for FSH, rDNA for immunoassay	92/510	RDNA-derived hFSH	60	2nd IRP for FSH and LH pituitary

The table shows the origin and relationship of unitages for the different preparations. All preparations were calibrated by *in vivo* bioassay in terms of the stated standard except preparations coded 94/632 and 92/510 for use in immunoassays.

^a Unless otherwise indicated.

^b Preparations no longer available.

isoform composition for the calibration of these assays. Alternatively, standards might be given a unitage based on the molar content of FSH in the ampoule or in reconstituted solution. The heterogeneous nature of FSH would necessitate that such a standard should have a defined isoform composition and that it can be reproduced for the preparation of replacement standards. Even with such a standard, discrepancies would arise between immunoassay systems that have different selectivities based on their epitopic recognition. Paradoxically, with the advances in preparation and analysis of therapeutic products, such a standard may also have applications in calibration of new therapeutics.

VI. Assay Systems Used for Measurement of FSH

Assays for FSH can be classified into a variety of groups (136). One broad classification might be those that determine some response of a biological system to stimulation with FSH (bioassays, both *in vivo* and *in vitro*), those that estimate high affinity binding to molecules which exhibit specific properties of molecular recognition (immunoassays, receptor assays and lectin binding assays), and those that determine structural features or molecular properties by physicochemical means.

A. Bioassays

1. *In vivo* bioassays. FSH was originally discovered and therefore defined on the basis of its biological action. Early studies (reviewed in Ref. 21) were confusing and contradictory. The activities being measured in unfractionated biological fluids (urine from pregnant and nonpregnant women) had to be resolved first into activities of placental and pituitary origin and subsequently into follicle stimulating and luteinizing activity. A number of different *in vivo* bioassays, which were essentially based upon the effects of aqueous extracts of pituitary, placenta, or urine on the reproductive tracts of mice and prepubertal rats, were used in the early stages of discovery of FSH. The initial methodology of Asheim and Zondek (137) was based on the biological effect of urine from pregnant women on the development of the reproductive tract in mice. Subsequently, increase in uterine weight and ovarian weight were used as biological endpoints (138). The assay developed in 1953 by Steelman and Pohley (139) based on the stimulation of ovarian weight in gonadotropin (LH)-treated immature rats, has proved to be a robust specific *in vivo* bioassay for FSH activity. This assay remains the basis of pharmacopeial monographs for the statutory determination of the FSH potency of therapeutic preparations (EP).

The major drawback of this assay is that the daily dosing regimen may preclude FSH forms that have a short half-life from exerting a biological effect. Evidence from studies on rDNA-derived FSH indicates that FSH isoforms with a pI value greater than about 5.1 exert no biological action in this assay (140). For most urinary derived preparations this may have little consequence since FSH produced in menopausal women is of an acidic nature, but it may be important in calibrating recombinant forms of FSH and in assigning specific activities related to protein content.

Acute or short-term *in vivo* bioassays that have been de-

scribed for LH are the ovarian ascorbic acid depletion test and the measurement of peripheral testosterone levels (141, 142). When preparations of different molecular composition are compared with each other in these two assays, different relative potencies are derived depending upon the assay type. No equivalent acute *in vivo* assays have been described for the determination of FSH. The *in vivo* effects of synthetic peptides corresponding to amino acids 34–37 of human FSH β -subunit have recently been evaluated using several parameters based on regulation of the estrous cycle (143). This illustrates other quantifiable FSH-dependent responses which might form the basis of a relevant bioassay for some preparations of potential therapeutic value that interfere with the action of FSH. Other endpoints in an *in vivo* bioassay could include the secretion of inhibins that have been related to subtle changes in FSH levels in women (144) and may allow an acute response to FSH to be determined.

In vivo biological activity is sometimes considered to be that which best defines FSH since it has two important components: that of biological action at the target tissue and that of biological clearance (145). However, use of genetic engineering techniques has enabled the modification of gonadotropins in terms of their biological activity by substitution of key amino acid sequences (146–148). The calibration of these materials as therapeutics will require careful thought. The current *in vivo* bioassay may be differently affected by forms of FSH with extended or shortened biological half-lives and may only detect some forms of FSH depending upon how the assay system is designed. Therefore, it might be necessary to redesign *in vivo* bioassays or to devise new assay systems to accommodate differences in activity of different molecular forms of FSH. Novel use of existing units, which may not reflect different aspects of the activity of some preparations, will need to be defined clearly to avoid confusion in their clinical usage. Clinicians using such preparations would need to distinguish between the expected patient responses to preparations with different properties calibrated in different ways. A unitage based on mass, although apparently providing a common basis, would not be appropriate unless combined with a range of physicochemical and/or biological assays since materials with different half lives exemplify the lack of relationship between mass and activity. Additionally, new unexpected activities can be generated (148) that will necessitate careful evaluation of the full biological potential of any chimeric molecules. If new materials produced through biotechnology are able to give significantly improved therapeutic treatments, then such problems would have to be overcome.

2. *In vitro* bioassays. A number of *in vitro* bioassays have been described (149–162), and this particular subject has been reviewed (163, 164). *In vitro* bioassays are largely based upon a quantifiable cellular response to stimulation with FSH. Such responses include stimulation of cAMP production (151), aromatase activity (154), or tissue plasminogen activator production (161) by Sertoli cells or granulosa cells in culture (*e.g.*, Refs. 155 and 157). More recent developments have included the use of cell lines transfected with the gene for expressing rat (165) or human (166, 167) FSH receptors and estimates of changes in cell shape or size (168) or cou-

pling of the gonadotropin receptor to a reporter gene (169). Recent advances in molecular biology may enable genetically engineered cell lines of various types to become common methods for estimating hormone activity (170). *In vitro* bioassays can provide very sensitive methods for estimating the biological activity of FSH in biological fluids (160) or isolated FSH isoforms (171). The two major drawbacks are that no comparisons of biological half-life can be made in such systems and that usually only one biochemical endpoint is measured. Furthermore, the systematic designs adopted for many *in vitro* assays may lead to biased results. Nevertheless, *in vitro* bioassays have proved to be valuable tools in elucidating the physiology of FSH.

B. High-affinity binding assays

1. *Immunoassays.* Immunoassays are widely used for clinical determination of FSH for diagnosis and in physiological studies because they are rapid, readily available, relatively cheap, and sensitive. Immunoassays are generally considered to be more precise than *in vivo* bioassays although, with the exception of a few documented cases (*e.g.*, Ref. 172), they are assumed to give no information about biological activity.

Early immunoassays for FSH were based on the RIA format (173), which gave robust assays that are still in use (174). However, RIAs have been largely superseded by assays based on monoclonal antibody technology (175). Most commercially available assays are now based on sandwiches of monoclonal or monoclonal-polyclonal antibodies with a variety of detection modes and are generally more sensitive and precise than one-site assays. The latter assays are highly specific and may exclude some forms of the hormone of interest (*e.g.*, Ref. 176). Thus, a hormone-specific polyclonal antibody-based assay that is less selective for hormone isotypes may be preferred for some purposes.

Although assays of apparently high specificity are commercially available, there is still considerable variability between the results of different assays for gonadotropins (124, 129–132, 177). The reasons for such variations have been ascribed to differences in calibration of different assay kits (130), cross-reactivity between gonadotropin subunits and nonlinearity between kit standard and internationally available standards (132), differential recognition of different samples obtained for example at different stages of the menstrual cycle (131), and varying dose-response characteristics between different assay systems (178). Details of the methods of calibration and sources and composition of kit and in-house standards are frequently unknown to the user, which makes evaluation of the standardization of calibration and hence comparisons between different immunoassay kits difficult. By comparison, therapeutic products and in-house standards are calibrated by a common methodology (pharmacopeial bioassay), and regulatory authorities may test the potency of products released onto the market to ensure compliance with statutory requirements and consistency.

2. *Epitopic structure and molecular recognition.* In many cases it is either not known or not stated what particular epitopes on the molecules are recognized by different antibodies even though the overall areas of greatest antigenicity have been

mapped on FSH (179–183) and hCG (184, 185). The methods used and results of epitopic mapping studies on gonadotropins have been succinctly reviewed (186). Epitopic maps of gonadotropins have several uses including the identification of antigenic regions, regions important for bioactivity (*e.g.*, for the purposes of designing vaccines), the functional importance of structural features such as the subunit contact sites (187) and receptor interaction sites (188–190), and the definition of topology (191).

The main antigenic epitopes of the subunits of FSH have been identified. Using a panel of 181 monoclonal antibodies, Berger *et al.* (186) identified nine antigenic sites; five on the α -subunit, two on the β -, and two dependent on the conformation of the $\alpha\beta$ -dimer. Dias and co-workers (179, 187, 189–193) have extensively mapped FSH epitopes and the effects of conformation on these. Although the α -subunits of the glycoprotein hormones have the same amino acid sequences in each of the four hormones, some of the identified epitopes on the FSH α -subunit (*e.g.*, 3A epitope) are different between the different glycoprotein hormone heterodimers, suggesting some flexibility of this epitope, the conformation of which is affected by binding to the β -subunit (192).

A study of affinities for recognized epitopes has been done on commercially available immunoassay kits for LH (194) with some success in identifying the causes of between-assay variation. Furthermore, standardization of epitopic recognition perhaps directed at “rigid” epitopes may contribute to further minimizing between-assay variability. Assay of variable epitopes in a hormone-specific fashion may enable further observations on how structural features of hormones change with different physiological conditions. Antibody responses to epitopes in the region covered by amino acid residues 33–53 of the FSH β -subunit have been found to both enhance (195) and neutralize (196) FSH action. These observations raise the possibility of new methods with which to manipulate ovarian function or to produce contraceptive agents.

Structural features of FSH known to change with different circumstances are the carbohydrate side chains attached to the protein backbone. Studies are currently underway to investigate whether antibody binding is affected by glycan heterogeneity. The current thinking derived from epitopic studies is that oligosaccharides do not play a significant role in antigenic structure of gonadotropins but that removal of or alteration of the structure of oligosaccharides may alter the affinity of binding of monoclonal antibodies (197). There are, however, reports of antibodies that can distinguish between native and desialyated hCG (198–202), and there may be some difference in orientation of the α -subunit assessed immunologically following chemical deglycosylation (200). Further evidence for antigenic recognition of oligosaccharide structures was derived from studies of antibodies raised against rDNA-derived hCG that contains glycans high in mannose as a result of the glycosylation produced in the baculovirus system (201). Direct screening of glycosides released from glycoproteins shows that some antibodies at least can recognize specific carbohydrate sequences (202). It is likely that there are both antibodies whose binding is not affected by alterations in sugar structure and antibodies whose binding is affected. For the purposes of defining assay

specificity, it therefore appears necessary to determine experimentally whether particular antibodies are affected by glycan structure.

In addition to differences in epitopic specificity, differences in antibody affinity, and differences in molecular recognition, there are other factors that contribute to the heterogeneity observed between immunoassay types. These factors can include assay type such as RIA *vs.* immunoradiometric assay or enzyme-linked immunosorbent assay (ELISA), etc., kinetics of the assay [few commercial assays are taken to completion (steady state) for the sake of rapid production of results], orientation of antibodies in the assay, and comparisons between different standards. Comparisons between commercial assay kits would be made easier if epitopic recognition and other properties of the antibodies, such as affinity for epitopic sites as well as source and composition of the kit and in-house standards, were clearly described.

3. Lectin-binding assays. Although the extent to which glycan structures may influence binding of antibodies to FSH molecules cannot be generally ascertained, the replacement of a detector antibody in an ELISA format with a labeled lectin gives rise to assays that can detect changes in oligosaccharide structures (203). This methodology is not generally quantitative but has been used to probe qualitative differences between different preparations of rDNA-derived human FSH preparations. It has also been used to independently confirm enzymatic modifications of gonadotropin molecules but has yet to be developed for application to samples of serum or pituitary tissue. Lectin-affinity chromatography (204), in which samples of serum are applied to a lectin column and eluted in a stepwise fashion with increasing concentrations of a suitable sugar, results in the identification of FSH isoforms that are either not bound to the column, weakly bound, or strongly bound. Gross differences in sugar structures are thus inferred. In the lectin-ELISA format, ratios of signals originating from terminal sialic acid, free galactose, and core structures can be determined and related to ELISA data for estimating the relative levels of these molecular structures in the preparation. Either protocol may be a first step in development of a clinically useful assay that provides qualitative data on changes in glycan structures on FSH (and other glycoproteins).

4. Receptor assays. Receptor assays involve the estimation of the binding of unknown samples to preparations of specific receptors of either natural or rDNA-derived origin. Early receptor assays were based upon the solubilized FSH receptor from calf testis (205–207). This has proved to be a robust assay and remains in use with further developments leading to a receptor assay that can be used for quantifying FSH in unextracted serum (208). Variations of the assay utilize intact cells or cell lines transfected with recombinant receptors. The inclusion of receptor assays in international collaborative studies has given rise to results that are relatively consistent in comparison with *in vitro* assays. This may result from the different properties that are determined by these two assay types (209).

A combination of a (recombinant) receptor and an antibody preparation in an ELISA-type format could give rise to

a useful and practical assay that estimates functional as well as immunologically reactive structural features (210).

5. Summary. Although high-affinity binding assays have provided much information about FSH, those that do not discriminate between different glycosylation forms of FSH may not be able to detect variant or antagonist forms of FSH (211). Analysis of binding kinetics can give results that are different for intact and deglycosylated FSH (212). These assays may also be affected by FSH-like molecules (213) or other inhibitory materials (214). The physiological basis of such molecules remains to be clarified.

C. Physicochemical assays

In impure preparations such as hMG, it is not possible to estimate FSH by physicochemical techniques, although in combination with immunoassays or *in vitro* bioassays, for example, the physicochemical properties of FSH molecules can be explored. The separation of different forms of pituitary or circulating FSH by physicochemical methods, such as zone electrophoresis with an immunoassay (215), or a bioassay as the detection method has been described (for a review see Ref. 216). Such studies show that FSH can change with different physiological or pathological situations but have not provided definitive structural information.

The availability of highly purified preparations derived from rDNA methods has now enabled a wider range of physicochemical techniques to be applied. The amino acid sequence and molecular mass (by mass spectrometry) of separated subunits can now be determined along with pI values for isolated bands on isoelectric focusing (IEF) gels. The structures of the glycan moieties and polypeptide chains can be determined by nuclear magnetic resonance (217, 218), and *in vivo* biological activity has been correlated with protein amount after separation of isoforms by IEF (140). However, despite all these methods for structural determination, no one method has been shown to predict biological activity directly.

Advanced techniques of mass spectrometry have been applied recently to the analysis of gonadotropins, particularly hCG (219–221). In these studies the heterogeneity derived from carbohydrate modifications resulted in limited ability to unambiguously identify hCG. After digestion by trypsin and separation of the various peptides before mass spectrometry, clearer signals were obtained, which enabled confirmation of hCG. This approach can be used to identify unambiguously a purified preparation of hCG for purposes such as drug enforcement (219) but would not enable quantitative determination of therapeutic products. It may, however, enable qualitative comparisons between different batches of therapeutic products (221) which could be used to assure batch-to-batch consistency.

Analysis by high-performance anion-exchange chromatography of glycosyl residues after enzymatic removal from the polypeptide backbone has been used to derive a hypothetical N-glycan charge value termed Z (222). The overall charge contributed by terminal sialic acids present on different glycosyl structures was calculated for a number of glycoproteins and was found to be a highly accurate and

reproducible measurable characteristic of glycoproteins. In light of the importance of sialic acid in regulating biological half-life and hence in *in vivo* activity, this could prove a useful step in estimating biological potency of therapeutic proteins by physicochemical means.

Although a number of advanced physicochemical techniques have been applied to characterize rDNA-derived hormones in detail (223–225), the determination of biological activity solely by physicochemical means requires further work.

VII. Interpretation of FSH Measurements

No assay system currently available clearly describes or estimates all features and actions of FSH. The relative amount of FSH determined by different assay types will depend upon the assay type chosen and the standard used. A major difficulty encountered in estimating FSH is the lack of clarity of definition of FSH. The concept of biological specificity associated with structural descriptions of FSH implies that it is a 'biological recognition' that defines FSH (and similar molecules) rather than a purely physicochemical definition. However, heterogeneity in the polypeptide backbone and in the glycosyl residues gives rise to a large number of isoforms that vary not only in molecular mass and overall charge but also in biological (and immunological) activity (potency and type of actions). It is this 2-fold heterogeneity of FSH that renders it difficult to define: chemically it is not possible to apply the concepts of purity and amount to an inherently heterogeneous substance; and biologically there is no single unique FSH bioactivity. Additionally, the matrix that contains FSH (*e.g.*, serum, plasma, follicular fluid) usually obviates any attempt at chemical or physicochemical analysis and may also interfere with biological assays.

A. Effect of different isoforms in different assay systems

1. *In vivo* bioassays. It would appear from experimentation that MCR is related to *in vivo* bioactivity (226). Those isoforms of FSH that are relatively low in sialic acid content, and are hence relatively basic in nature, have a relatively low potency in *in vivo* bioassays (140) due presumably to their rapid clearance from the circulation. However, there are conflicting reports that different isoforms of FSH do not exhibit differences in clearance (227). Furthermore, while differences in *in vitro* bioactivity were not found to be reflected by differences in clearance of *in vivo* bioactivity (228), *in vivo* biological activity of LH was found by others (42) to reflect *in vitro* biological activity rather than clearance. The reasons for these discrepancies in the literature are unclear but may be related to selection of endpoint in the assay (chronic effect *vs.* acute effect) and structural details of pituitary and circulating FSH in relationship to the mechanisms of clearance.

Studies carried out to correlate biological activity with isoform profile showed (140) that the protein amount, as determined by laser densitometry of IEF gels, correlated with bioactivity, as determined by ovarian weight augmentation, only for those forms of FSH that have a pI of less than 5.1. An increase in the proportion of protein with a pI of greater than 5.1 resulted in a decrease in *in vivo* biological activity.

It is not known whether the same would be true in an acute or short term *in vivo* bioassay. The response, if any, that these basic forms of FSH evoke may be transient and thus may not contribute to the endpoint determined in the Steelman-Pohley test. If rDNA-derived forms of FSH are selected for a relatively short half-life to enable fine tuning of the ovarian cycle (229), then the format of the *in vivo* bioassay will need to be redesigned for calibration of such materials.

2. *In vitro* bioassays. *In vitro* bioassays can offer insights by enabling the biological activity of short-lived species to be determined and specific cellular responses to be evaluated. However, variations in assay design and standards can lead to different interpretations of physiological events. Thus, the biological signal measured in one *in vitro* bioassay of FSH increases in the mid- to late luteal phase, when immunologically reactive FSH is apparently decreasing (167), and the biological activity of FSH appears to continue increasing even when estradiol levels are declining. Other reports have found an unchanging biological signal (159), an increase in the early follicular phase (230), and an increase in the mid to late luteal phase (167). There is strong evidence for specific effects of different FSH forms, which are produced at different stages of the cycle as proposed by Chappel *et al.* (231). Thus, FSH bioactivity rather than amount may be more important physiologically. Development of *in vitro* models that can distinguish between specific actions of FSH, such as recruitment and growth of follicles or the induction of hormonal components of follicular activity or which have multiple endpoints (75), would broaden our knowledge further.

3. *Immunoassays*. The effect of isoform composition on immunoassay determinations is not resolved. It is claimed that immunoassays are blind to the carbohydrate content of FSH and while the antigenic sites of FSH do not appear to involve oligosaccharides, it is likely that differences in overall charge resulting from variations in sugar structures could affect antibody binding (232). Whereas some immunoassay types may not provide an estimate of bioactive circulating FSH (232, 233), others have been reported to reflect biological activity well (172). Certainly there is significant variation in the estimates of activity of the same preparations of FSH by immunoassays (124) that has been observed in a recent WHO international collaborative study (123).

B. Effect of different forms of FSH on FSH determinations

1. *Determination of FSH activity by in vivo bioassays and the relationship between in vivo bioactivity and clinical efficacy*. The potency of therapeutic products is derived from *in vivo* bioassays in terms of in-house standards, which are calibrated in terms of WHO International Standards. Comparisons in international collaborative studies suggest that continuity and consistency of estimates may be obtained by *in vivo* bioassay for therapeutic products although the limits of activity defined by the pharmacopeia indicate the relative lack of precision when a limited number of assays are done. Moreover, although a common standard and a common assay method are intended to maintain consistent unitages for patients irrespective of the source of the material used, this cannot be guaranteed (Sections VI and VII).

TABLE 4. Summary of examples of assays for FSH and their main uses, advantages, and disadvantages

Assay type	Uses and Main advantages	Main disadvantages
Bioassays	Measure biological activity.	Do not necessarily imply any information on amount of substance; require reference material that is difficult to define
<i>In vivo</i> assays	Useful for calibrating therapeutic products; take account of biological clearance	Cumbersome, insensitive
<i>In vitro</i> assays	Sensitive, specific, high throughput; useful for measuring physiological samples	Do not take account of biological clearance; single endpoint often measured; difficult to standardize
Immunoassays	Measure immunoreactivity; useful diagnostically	Require reference material that is difficult to define; epitopes often poorly defined
RIA, ELISA, Lectin-ELISA	Sensitive and specific with high throughput; lectin may provide some structural information	May be too specific; do not necessarily imply any information about biological activity or amount
Physicochemical assays		
Electrophoresis Chromatography	Can be used quantitatively in absolute terms for some determinations (<i>e.g.</i> , protein concentration)	Require pure samples in large quantities
Mass spectrometry	Can be used to characterize structural details (<i>e.g.</i> , identify peptide map for drug testing)	Cannot (yet) infer information about biological activity; some systems, <i>e.g.</i> , mass spectrometry, very expensive
Chemical analysis		
NMR		

The biological action of FSH determined in the Steelman-Pohley assay is ovarian growth against a background of excess LH/hCG in immature rats. The desired clinical action in patients is the recruitment and stimulation of a single follicle or a cohort of follicles and the stimulation of estradiol production, possibly against a background of low endogenous LH levels.

The advent of therapeutic forms of FSH made from "pure FSH" derived from rDNA-sources (234) has led to the application of physicochemical techniques to FSH analysis (235, 236), to comparative analysis of *in vitro* and *in vivo* biological activity (237–240), and to a plethora of studies in which recombinant DNA-derived hFSH has been evaluated for toxicity (241), comparative pharmacokinetics (242, 243), and clinical pharmacology (122, 244–247). In many studies urinary and well-characterized recombinant materials have been compared for efficacy, quality, and safety (*e.g.*, Ref. 248). Most studies have found little difference between therapeutics derived from different sources. However, there is a significant body of data supporting the conclusion that recombinant preparations are more clinically efficacious than their urinary counterparts on a unit-for-unit basis (121, 249). Assuming that the materials under test in these studies were calibrated against WHO International Standards raises questions about the validity of the *in vivo* bioassay for calibration of therapeutic products from different sources and about the relationship of the biological assay of FSH to its clinical effectiveness and safety. Even when allowed variability between preparations defined by pharmacopeial monographs is taken into account (actual potency may be between 80–125% of the stated potency), it is difficult to explain why a recombinant DNA-derived material should be more effective in inducing follicular growth than a highly purified urinary material.

One explanation is that recombinant DNA-derived FSH, with a higher content of basic isoforms that do not contribute to the *in vivo* bioassay (140), may more closely resemble those FSH forms produced at midcycle than urinary FSH and may

therefore be more effective at producing the required physiological response (76). It has also been reported that relatively basic isoforms of rDNA-derived FSH are more effective in stimulating follicular growth *in vitro* (250).

2. *Determination of FSH by immunoassay and clinical diagnosis.* In the diagnosis of clinical conditions the level of biologically active FSH in the circulation is of importance. However, diagnostic tests are generally made by immunoassay that may recognize FSH molecules that are not biologically active. Conversely, some highly specific assays may discriminate against some forms of FSH, although this is a matter of controversy. Some anti-LH antibodies are reported not to recognize some forms of LH that arise by genetic variation (251, 252). There are reports of genetic variants of FSH that have been associated with delayed sexual development and infertility (253–255) but these are rare and result in drastic alterations to the FSH molecule rather than to an antigenic epitope as is the case with the more common LH polymorphism. Whether antibody selectivity could compromise diagnosis is not clear. Nevertheless the particular selectivity of any one assay system is seldom known, and it is therefore not possible to define FSH in terms of immunoreactivity. Since FSH (and LH) levels and isoform composition change drastically throughout life and through menstrual cycles, clinical determinations usually require some additional clinical data such as stage of cycle or repeat measurements to distinguish between different diagnostic possibilities. A combination of quantitative and qualitative assays would be a major advance in clinical utility of gonadotropin determinations.

Other complications of the gonadotropin system that have been implicated in disorders of reproduction and that may affect clinical diagnoses based on FSH determinations include mutations in the FSH receptor and circulating antibodies against FSH (256–258).

In combination with immunoassays, *in vitro* bioassays have been used to derive a biological activity-immunological activity (B:I) ratio. The rationale behind this concept has been

critically discussed (259). Unless either the biological activity or the immunoreactivity of different preparations can be shown to be constant for each set of assay systems in use, then the results of such studies will be misleading. Data derived from international collaborative studies indicate that the B:I ratio is not a stable parameter. Estimates of activity of different preparations obtained from both *in vitro* bioassays and immunoassays were variable, reflecting the different specificities of the different assay systems. Although B:I ratios may be misleading, a comparison of the results from receptor assays, immunoassays, and *in vitro* bioassays can provide an indication of changing isoform profile or of factors that interfere in FSH action in some circumstances (205, 206).

VIII. Conclusions

FSH is a heterogeneous hormone that can be defined in terms of both its molecular structure and its biological function. The molecular structure of FSH has been largely determined but variation in key structures leads to heterogeneity and renders impossible a definition of a single molecular entity as FSH. Biologically, FSH exerts multiple effects at its target tissues so that there is no single action that defines FSH.

Measurements of FSH are made using a variety of methods (summarized in Table 4), most of which are biological in nature. However, the interaction of molecular heterogeneity and biological actions and the difficulty in defining a standard preparation of the same type as the unknown sample that is to be measured can lead to uncertainties. This is particularly true if the characteristics of the standard and the assay system used are not clearly specified.

The World Health Organization has made available FSH standards derived from different sources that are representative of the main sources of bulk materials used in the preparation of therapeutic products. These international standards have similar biological actions to one another and to therapeutic products in the pharmacopeially defined *in vivo* bioassay. The use of appropriate standards for calibration of therapeutic products in the pharmacopeial assay has, to a large extent, achieved continuity of unitage of therapeutic products. However, these standards may be less suitable for general use in a range of assays where the interaction of molecular and biological heterogeneity of FSH may lead to inconsistent estimates with the "measured amount of FSH" depending on selection both of the standard and of the assay system.

As both the molecular structure of FSH and its biological actions are more clearly characterized, the need for appropriate standards for particular assays and purposes may become apparent. For some highly purified preparations, physicochemical techniques may become more useful. The availability of standards of defined isoforms of FSH might enable determination of the specificity of various immunoassays, and this might serve to clarify the meaning of some of these measurements. The definition of the particular isoforms that are of clinical relevance might permit the development of assays specific for them, as well as indicating the types of preparations that might be appropriate as standards.

FSH will continue to be used therapeutically and diagnostically in assessing and treating disorders of the reproductive system. Thus, the scientific community should be aware of the need to specify as far as possible what is meant by any particular measurement of FSH and, in particular, should be aware that such measurement is not meaningful without definition of both the standard and the measuring method used.

References

1. Lunenfeld B, Lunenfeld E 1997 Gonadotropic preparations — lessons learned. *Fertil Steril* 67:812–814
2. British Pharmacopoeia Commission 1998 Monograph for Menotrophin. The Stationary Office, London, vol 1: 855–857
3. Fauser BCJM, Van Heusden AM 1997 Manipulation of human ovarian function: physiological concepts and clinical consequences. *Endocr Rev* 18:71–106
4. Balen AH, Braat DDM, West C, Patel A, Jacobs HS 1994 Cumulative conception and live birth rates after the treatment of anovulatory infertility. An analysis of the safety and efficacy of ovulation induction in 200 patients. *Hum Reprod* 9:1563–1570
5. Ben-Rafael Z, Levy T, Schoemaker J 1995 Pharmacokinetics of follicle-stimulating hormone: clinical significance. *Fertil Steril* 63:689–700
6. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, Hamilton-Fairley D, Franks S 1996 Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. *J Clin Endocrinol Metab* 81:3821–3824
7. Manasco PK, Umbach DM, Muly SM, Godwin DC, Negro-Vilar A, Culler MD, Underwood LE 1995 Ontogeny of gonadotropin, testosterone, and inhibin secretion in normal boys through puberty based on overnight serial sampling. *J Clin Endocrinol Metab* 80:2046–2052
8. Balen AH, Jacobs HS 1997 Male factor infertility. In: Balen AH, Jacobs HS (eds) *Infertility in Practice*. Churchill Livingstone, London, pp 213–240
9. Balen AH, Jacobs HS 1997 Assisted conception. In: Balen AH, Jacobs HS (eds) *Infertility in Practice*. Churchill Livingstone, London, pp 255–286
10. Muasher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, Liu HC, Jones GS, Rosenwaks Z 1988 The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and *in vitro* fertilisation outcome. *Fertil Steril* 50:298–307
11. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z 1989 Follicle stimulating hormone levels on cycle day 3 are predictive of *in vitro* fertilisation outcome. *Fertil Steril* 51:651–654
12. Cameron IT, O'Shea FC, Rolland JM, Hughes EG, de Kretser DM, Healy DL 1988 Occult ovarian failure: a syndrome of infertility, regular menses, and elevated follicle stimulating hormone concentrations. *J Clin Endocrinol Metab* 67:1190–1194
13. Koskinen P, Penttila T-A, Anttila L, Erkkola R, Irjala K 1996 Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. *Fertil Steril* 65:517–522
14. Balen AH, Jacobs HS 1997 Investigating infertility. In: Balen AH, Jacobs HS (eds) *Infertility in Practice*. Churchill Livingstone, London, pp 39–114
15. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS 1995 Polycystic ovary syndrome. The spectrum of the disorder in 1741 patients. *Hum Reprod* 10:2107–2111
16. Santoro N, Brown JR, Adel T, Skurnick JH 1996 Characterisation of reproductive hormonal dynamics in the perimenopause. *J Clin Endocrinol Metab* 81:1495–1501
17. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR 1996 Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. *J Clin Endocrinol Metab* 81:1038–1045
18. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall J 1997 Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 82:2248–2256

19. Leach RE, Moghissi KS, Randolph JF, Reame NE, Blacker CM, Ginsburg KA, Diamond MP 1997 Intensive hormone monitoring in women with unexplained infertility: evidence for subtle abnormalities suggestive of diminished ovarian reserve. *Fertil Steril* 68:413–420
20. Bodis J, Torok A, Tinneburg HR 1997 LH/FSH ratio as a predictor of ovarian hyperstimulation syndrome. *Hum Reprod* 12:869–870
21. Jeffcoate SL 1994 From TNA to DNA: 60 years of follicle stimulating hormone (FSH) in gynaecology. In: *The Yearbook of the RCOG. Royal College of Obstetricians and Gynecologists*, London, chapter 6, pp 55–67
22. Shome B 1974 Human follicle stimulating hormone: first proposal for the amino acid sequence of the hormone-specific, β subunit (hFSH β). *J Clin Endocrinol Metab* 39:203–205
23. Shome B, Parlow AF 1974 Human follicle stimulating hormone (hFSH): first proposal for the amino acid sequence of the α -subunit (hFSH α) and first demonstration of its identity with the alpha subunit of human luteinizing hormone (hLH α). *J Clin Endocrinol Metab* 39:199–202
24. Rathnam P, Saxena BB 1975 Primary amino acid sequence of follicle-stimulating hormone from human pituitary glands. I. α subunit. *J Biol Chem* 250:6735–6746
25. Saxena BB, Rathnam P 1976 Amino acid sequence of the β subunit of follicle-stimulating hormone from human pituitary glands. *J Biol Chem* 251:993–1005
26. Fujiki Y, Rathnam P, Saxena BB 1978 Amino sequence of the β -subunit of the follicle-stimulating hormone from equine pituitary glands. *J Biol Chem* 253:5363–5368
27. Rathnam P, Fujiki Y, Landefeld TD, Saxena BB 1978 Isolation and amino acid sequence of the α -subunit of follicle-stimulating hormone from equine pituitary glands. *J Biol Chem* 253:5355–5362
28. Hayashi T, Hanaoka Y, Hayashi H 1992 The complete amino acid sequence of the follitropin β -subunit of the bullfrog, *Rana catesbeiana*. *Gen Comp Endocrinol* 88:144–150
29. Hayashi H, Hayashi T, Hanoka Y 1992 Amphibian lutropin and follitropin from the bullfrog *Rana catesbeiana*. Complete amino acid sequence of the α subunit. *Eur J Biochem* 203:185–191
30. Hara K, Rathnam P, Saxena BB 1978 Structure of the carbohydrate moieties of α subunits of human follitropin, lutropin and thyrotropin. *J Biol Chem* 253:1582–1591
31. Baenziger JU, Green ED 1988 Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. *Biochim Biophys Acta* 947:287–306
32. Green ED, Baenziger JU 1988 Asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. II. Distributions of sulfated and sialylated oligosaccharides on bovine, ovine and human pituitary glycoprotein hormones. *J Biol Chem* 263:36–44
33. Baenziger JU, Green ED 1991 Structure, synthesis and function of the asparagine-linked oligosaccharides on pituitary glycoprotein hormones. *Biol Carb* 3:1–46
34. Maurer RA, Beck A 1986 Isolation and nucleotide sequence analysis of a cloned cDNA encoding the β -subunit of bovine follicle stimulating hormone. *DNA* 5:363–369
35. Kato Y 1988 Cloning and DNA sequence analysis of the cDNA for the precursor of porcine follicle stimulating hormone (FSH) β subunit. *Mol Cell Endocrinol* 55:107–112
36. Lawrence SB, Vanmontfort DM, Tisdall DJ, McNatty KP, Fidler AE 1997 The follicle-stimulating hormone β -subunit gene of the common brushtail possum (*Trichosurus vulpecula*): analysis of cDNA sequence and expression. *Reprod Fertil Dev* 9:795–801
37. Pierce JG, Parsons TF 1981 Glycoprotein hormones: structure and function. *Annu Rev Biochem* 50:465–495
38. Wilson CA, Leigh AJ, Chapman AJ 1990 Gonadotropin glycosylation and function. *J Endocrinol* 125:3–14
39. Beitins IZ, Padmanabhan V 1991 Bioactivity of gonadotropins. *Endocrinol Metab Clin North Am* 20:85–120
40. Hartree AS, Renwick AGC 1992 Molecular structures of glycoprotein hormones and functions of their carbohydrate components. *Biochem J* 287:665–679
41. Thotakura NR, Blithe DL 1995 Glycoprotein hormones: glycobiochemistry of gonadotrophins, thyrotropin and free α subunit. *Glycobiology* 5:3–10
42. Stanton PG, Burgon PG, Hearn MTW, Robertson DM 1996 Structural and functional characterisation of hFSH and hLH isoforms. *Mol Cell Endocrinol* 125:133–141
43. McLachlan RI, Wreford NG, O'Donnell L, de Kretser DM, Robertson DM 1996 The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. *J Endocrinol* 148:1–9
44. Kumar TR, Wang Y, Lu N, Matzuk MM 1997 Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. *Nat Genet* 15:201–204
45. Richards JS 1994 Hormonal control of gene expression in the ovary. *Endocr Rev* 15:725–751
46. Christenson LK, Stouffer RL 1997 Follicle-stimulating hormone and luteinizing hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by macaque granulosa cells from pre- and periovulatory follicles. *J Clin Endocrinol Metab* 82:2135–2142
47. Li R, Phillips DM, Moore A, Mather JP 1997 Follicle-stimulating hormone induces terminal differentiation in a predifferentiated rat granulosa cell line (ROG). *Endocrinology* 138:2648–2657
48. Sharma OP, Flores JA, Leong DA, Veldhuis JD 1994 Cellular basis for follicle-stimulating hormone-stimulated calcium signaling in single rat Sertoli cells: possible dissociation from effects of adenosine 3',5'-monophosphate. *Endocrinology* 134:1915–1923
49. Laphorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, Morgan FJ, Isaacs NW 1994 Crystal structure of chorionic gonadotrophin. *Nature* 369:455–461
50. Wu H, Lustbader JW, Liu Y, Canfield RE, Hendrickson WA 1994 Structure of human chorionic gonadotropin at 2.6 Å resolution from MAD analysis of the selenomethionyl protein. *Structure* 2:245–258
51. Furuhashi M, Ando H, Bielinska M, Pixley MR, Shikone T, Hsueh AJW, Boime I 1994 Mutagenesis of cysteine residues in the human gonadotropin α subunit. *J Biol Chem* 269:25543–25548
52. Sato A, Perlas E, Ben-Menaheem D, Kudo M, Pixley MR, Furuhashi M, Hsueh AJW, Boime I 1997 Cystine knot of the gonadotropin α subunit is critical for intracellular behaviour but not for *in vitro* biological activity. *J Biol Chem* 272:18098–18103
53. Roth KE, Liu C, Shepard BA, Shaffer JB, Dias JA 1993 The flanking amino acids of the human follitropin β -subunit 33–53 region are involved in assembly of the follitropin heterodimer. *Endocrinology* 132:2571–2577
54. Furuhashi M, Suzuki S, Suganuma N 1996 Disulfide bonds 7–31 and 59–87 of the α subunit play a different role in assembly of human chorionic gonadotropin and lutropin. *Endocrinology* 137:4196–4200
55. Liu C, Roth KE, Lindaup Shepard BA, Shaffer JB, Dias JA 1993 Site-directed alanine mutagenesis of Phe³³, Arg³⁵, and Arg⁴²-Ser⁴³-Lys⁴⁴ in the human gonadotropin α -subunit. *J Biol Chem* 268:21613–21617
56. Yoo J, Zeng H, Ji I, Murdoch WJ, Ji TH 1993 COOH-terminal amino acids of the α -subunit play common and different roles in human chorionic gonadotropin and follitropin. *J Biol Chem* 268:13034–13042
57. Zeng H, Ji I, Ji TH 1995 Lys⁹¹ and His⁹⁰ of the α -subunit are crucial for receptor binding and hormone action of follicle-stimulating hormone (FSH) and play hormone-specific roles in FSH and human chorionic gonadotropin. *Endocrinology* 136:2498–2953
58. Lindaup Shepard B, Roth KE, Dias JA 1994 Identification of amino acids in the c-terminal region of human follicle-stimulating hormone (FSH) β -subunit involved in binding to the human FSH receptor. *Endocrinology* 135:1235–1240
59. Xia H, Chen F, Puett D 1994 A region in the human glycoprotein hormone α -subunit important in holoprotein formation and receptor binding. *Endocrinology* 134:1768–1770
60. Ward DN, Moore WT 1979 Comparative study of mammalian glycoprotein hormones. In: Alexander NJ (ed) *Animal Models for Research on Contraception and Fertility*. Harper & Row, New York, pp 151–164
61. Mort AJ, Lamport DTA 1977 Anhydrous hydrogen fluoride deglycosylates glycoproteins. *Anal Biochem* 82:289–309
62. Manjunath P, Sairam MR 1982 Biochemical, biological and immunological properties of chemically deglycosylated human chorionic gonadotropin. *J Biol Chem* 257:7109–7115
63. Calvo FO, Keutmann HT, Bergert ER, Ryan RJ 1986 Deglycosylated human follitropin: characterisation and effects on adenosine cyclic 3',5'-phosphate production in porcine granulosa cells. *J Biochem* 25:3938–3943

64. Dufau ML, Catt KJ, Tsuruhara T 1971 Retention of *in vitro* biological activities by desialylated human luteinizing hormone and chorionic gonadotropin. *Biochem Biophys Res Commun* 44:1022-1029
65. Van Hall EV, Vaitukaitis JL, Ross GT, Hickman JW, Ashwell G 1971 Immunological and biological activities of hCG following progressive desialylation. *Endocrinology* 88:456-64
66. Tsuruhara T, Dufau ML, Hickman JW, Catt KJ 1972 Biological properties of hCG after removal of terminal sialic acid and galactose residues. *Endocrinology* 91:296-301
67. Matzuk MM, Boime I 1989 Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. *Biol Reprod* 40:48-53
68. Manjunath P, Sairam MR 1983 Enhanced thermal stability of chemically deglycosylated human chorionic gonadotropin. *J Biol Chem* 258:3554-3558
69. Sairam MR, Bhargavi GN 1985 A role for glycosylation of the α subunit in transduction of biological signal in glycoprotein hormones. *Science* 229:65-67
70. Matzuk MM, Boime I 1988 The role of asparagine-linked oligosaccharides of the α subunit in the secretion and assembly of human chorionic gonadotropin. *J Cell Biol* 106:1049-1059
71. Matzuk MM, Boime I 1988 Site-specific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin β subunit. *J Biol Chem* 263:17106-17111
72. Feng W, Huth JR, Norton SE, Ruddon RW 1995 Asparagine-linked oligosaccharides facilitate human chorionic gonadotropin β subunit folding but not assembly of prefolded β with α . *Endocrinology* 136:52-61
73. Feng W, Matzuk MM, Mountjoy K, Bedows E, Ruddon RW, Boime I 1995 The asparagine-linked oligosaccharides of the human chorionic gonadotropin β subunit facilitate correct disulfide bond pairing. *J Biol Chem* 270:11851-11859
74. Chappel SC 1995 Heterogeneity of follicle stimulating hormone: control and physiological function. *Hum Reprod Update* 1:479-487
75. Ulloa-Aguirre A, Midgley Jr AR, Beitins IZ, Padmanabhan V 1995 Follicle stimulating isohormones: characterization and physiological relevance. *Endocr Rev* 16:765-787
76. Wide L, Bakos O 1993 More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at mid-cycle compared with follicular or luteal phase. *J Clin Endocrinol Metab* 76:885-889
77. Wide L, Albertsson-Wikland K, Phillips DJ 1996 More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children. *J Clin Endocrinol Metab* 81:216-221
78. Phillips DJ, Wide L 1994 Serum gonadotropin isoforms become more basic after an exogenous challenge of gonadotropin releasing hormone in children undergoing pubertal development. *J Clin Endocrinol Metab* 79:814-819
79. Wide L 1989 Follicle stimulating hormone in anterior pituitary glands from children and adults differ in relation to sex and age. *J Endocrinol* 123:519-529
80. Wide L, Hobson BM 1983 Qualitative difference in follicle stimulating hormone activity in the pituitaries of young women compared to that of men and elderly women. *J Clin Endocrinol Metab* 56:371-375
81. Ulloa-Aguirre A, Schwall R, Cravioto A, Zambrano E, Damian-Matsumura P 1992 Effects of gonadotropin-releasing hormone, recombinant human activin-A and sex steroid hormones upon the follicle-stimulating isohormones secreted by rat anterior pituitary cells in culture. *J Endocrinol* 134:97-106
82. Harsch IA, Simoni M, Nieschlag E 1993 Molecular heterogeneity of serum follicle-stimulating hormone in hypogonadal patients before and during androgen replacement therapy and in normal men. *Clin Endocrinol (Oxf)* 39:173-180
83. Wide L, Naessen T 1994 17β -oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing after menopause. *Clin Endocrinol (Oxf)* 40:783-789
84. Zambrano E, Olivares A, Mendez JP, Guerrero L, Diaz-Cueto L, Veldhuis JD, Ulloa-Aguirre A 1995 Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle. *J Clin Endocrinol Metab* 80:1647-1656
85. Creus S, Pellizzari E, Cigorruga SB, Campo S 1996 FSH isoforms: bio- and immuno-activities in post menopausal and normal menstruating women. *Clin Endocrinol (Oxf)* 44:181-189
86. Wide L, Naessen T, Eriksson K, Rune C 1996 Time-related effects of a progestogen on the isoforms of serum gonadotrophins in 17β -oestradiol treated post-menopausal women. *Clin Endocrinol (Oxf)* 44:651-658
87. Simoni M, Weinbauer GF, Chandolia RK, Nieschlag E 1992 Microheterogeneity of pituitary follicle-stimulating hormone in male rats: differential effects of the chronic androgen deprivation induced by castration or androgen blockade. *J Mol Endocrinol* 9:175-182
88. Phillips DJ, Moore LG, Hudson NL, Lun S, McNatty KP 1995 Effects of ovariectomy and FecB^B genotype on the median charge and circulating half-life of pituitary isoforms of ewes. *J Reprod Fertil* 104:27-31
89. McFarlane IG 1983 Hepatic clearance of serum glycoproteins. *Clin Sci* 64:127-135
90. Markkanen SO, Rajaniemi HJ 1979 Uptake and subcellular catabolism of human chorionic gonadotropin in the proximal tubule cells of rat kidney. *Mol Cell Endocrinol* 13:181-190
91. Morell AG, Gregoriadis G, Scheinberg IH, Hickman J, Ashwell G 1971 The role of sialic acid in determining the survival of glycoproteins in the circulation. *J Biol Chem* 246:1461-1467
92. Ashwell G, Harford J 1982 Carbohydrate specific receptors of the liver. *Annu Rev Biochem* 51:531-554
93. Fiete D, Srivastava V, Hindsgaul O, Baenziger JU 1991 A hepatic reticuloendothelial cell receptor specific for $SO_4-4GalNAc\beta 1,4GlcNAc\beta 1,2Man\alpha$ that mediates rapid clearance of lutropin. *Cell* 67:1103-1110
94. Baenziger JU, Kumar S, Brodbeck RM, Smith PL, Beranek MC 1992 Circulatory half life but not interaction with lutropin/chorionic gonadotropin receptor is modulated by sulfation of bovine lutropin oligosaccharides. *Proc Natl Acad Sci USA* 89:334-338
95. Szkudlinski MW, Thotakura NR, Tropea JE, Grossman M, Weintraub BD 1995 Asparagine-linked oligosaccharide structures determine clearance and organ distribution of pituitary and recombinant thyrotropin. *Endocrinology* 136:3325-3330
96. Lefort GP, Stolk JM, Nisula BC 1984 Evidence that desialylation and uptake by hepatic receptors for galactose-terminated glycoproteins are immaterial to the metabolism of human chorionic gonadotropin in the rat. *Endocrinology* 115:1551-1557
97. Schwartz AL, Fridovich SE, Knowles BB, Lodish HF 1981 Characterisation of the asialoglycoprotein receptor in a continuous hepatoma cell line. *J Biol Chem* 256:8878-8881
98. Chang T-M, Chang CL 1988 Hepatic uptake of asialoglycoprotein is different among mammalian species due to different receptor distribution. *Biochim Biophys Acta* 942:57-64
99. Rose M, Longley J, Rafferty B 1996 Uptake of desialylated human chorionic gonadotropin (hCG) via the asialoglycoprotein receptor on cultured liver cell lines. *J Endocrinol* 148 [Suppl]:30
100. Roos P 1968 Human follicle stimulating hormone: its isolation from the pituitary gland and from postmenopausal urine and a study of some chemical, physical immunological and biological properties of the hormone from these two sources. *Acta Endocrinol (Copenh)* 59 [Suppl 131]:1-93
101. Sebok K, Sairam MR, Cantin M, Mohapatra SK 1987 Distribution of follitropin and deglycosylated follitropin in the rat: a quantitative and radioautographic study. *Mol Cell Endocrinol* 52:185-197
102. Renkin EM, Gilmore JP 1973 Glomerular filtration. In: Orloff J, Berliner RW (eds) *Renal Physiology*. American Physiological Society, Washington DC, chapter 9, pp 185-248
103. Ghinea N, Milgrom E 1995 Transport of protein hormones through the vascular endothelium. *J Endocrinol* 145:1-9
104. Wehmann RE, Blithe DL, Flack MR, Nisula BC 1989 Metabolic clearance rate and urinary clearance of purified [beta]-core. *J Clin Endocrinol Metab* 69:510-517
105. Campbell N 1921 *What is Science?* Methuen & Co., London
106. Zender R 1989 Measurements in biological systems. Metrological principles and terminology. *Scand J Clin Lab Invest* 49:3-10
107. Dybkaer R 1989 Metrological problems and requirements in life sciences. *Scand J Clin Lab Invest* 49:104-107
108. Buttner J 1995 Philosophy of measurement by means of immunoassays. *Scand J Clin Lab Invest* 51:11-20

109. **Dybkaer R** 1990 General metrological requirements. *Scand J Clin Lab Invest Suppl* 198:20–25
110. **Jerne NK, Wood EC** 1949 The validity and meaning of the results of biological assays. *Biometrics* 5:272–299
111. **Miles AA** 1951 Biological standards and the measurement of therapeutic activity. *Br Med Bull* 7:283–291
112. **Maaloe O, Jerne NK** 1952 The standardization of immunological substances. *Annu Rev Microbiol* 6:349–366
113. **Finney DJ** 1978 *Statistical Method in Biological Assay*. Charles Griffin & Co., London
114. **Burn JH** 1930 The errors of biological assay. *Physiol Rev* 10:146–169
115. **WHO Expert Committee on Biological Standardization** 1959 Human menopausal gonadotrophin. *World Health Organ Tec Rep Ser* 172:9
116. **WHO Expert Committee on Biological Standardization** 1964 Human menopausal gonadotrophin. *World Health Organ Tec Rep Ser* 293:12
117. **Storring PL, Dixon H, Bangham DR** 1976 The first international standard for human urinary FSH and for human urinary LH (ICSH), for bioassay. *Acta Endocrinol (Copenh)* 83:700–710
118. **Bangham DR** 1976 Standardization in peptide hormone immunoassays: principles and practice. *Clin Chem* 22:957–963
119. **Garrett PE** 1989 The enigma of standardization for LH and FSH assays. *J Clin Immunoassay* 12:18–20
120. **Rose MP** 1998 Follicle stimulating hormone: international standards and reference preparations for the calibration of immunoassays and bioassays. *Clin Chim Acta* 273:103–117
121. **Coelingh Bennink HJ, Fauser BC, Out HJ** 1998 Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. *European Puregon Collaborative Anovulation Study Group. Fertil Steril* 69:19–25
122. **Howles CM, Loumaye E, Beltrami V, Porchet HC, Le Cotonne H-Y, Giroud D, Galazka A** 1994 Experiences with recombinant human follicle stimulating hormone (Gonal-F). In: Schoemaker J (ed) *FSH The Essential Hormone* (The proceedings of a special symposium held at the VIII World Congress on Human Reproduction Joint IV World Conference on Fallopian Tube in Health and Disease, April 1993, Bali, Indonesia). Parthenon Publishing Group, Carnforth, UK, pp 37–49
123. **Rose MP, Gaines-Das RE** 1998 Characterisation, calibration and comparison by international collaborative study of international standards (IS) for the calibration of therapeutic preparations of FSH. *J Endocrinol* 158:97–114
124. **Vermes I, Bonte HA, van der Sluijs-Veer G, Schoemaker J** 1991 Interpretations of five monoclonal immunoassays of lutropin and follitropin: effects of normalisation with WHO Standard. *Clin Chem* 37:415–421
125. **Storring PL, Gaines Das RE** 1989 The International Standard for Pituitary FSH: collaborative study of the standard and of four other purified human FSH preparations of differing molecular composition by bioassays, receptor assays and different immunoassay systems. *J Endocrinol* 123:275–293
126. **Rose MP, Gaines-Das RE** 1996 The changing nature of immunoassays for FSH: comparisons of serum samples and standard materials in two different international collaborative studies. *Hum Reprod* 11 (Abstract book 1)174
127. **Zaidi AA, Froyssa B, Diczfalusy E** 1982 Biological and immunological properties of different molecular species of human follicle-stimulating hormone: electrofocusing profiles of eight highly purified preparations. *J Endocrinol* 92:195–204
128. **Simoni M, Jockenhovel F, Nieschlag E** 1993 Biological and immunological properties of the international standard for FSH 83/575: isoelectrofocusing profile and comparison with other FSH preparations. *Acta Endocrinol (Copenh)* 128:281–288
129. **Seth J, Hanning I, Bacon RRA, Hunter WM** 1989 Progress and problems in immunoassays for serum pituitary gonadotrophins: evidence from the UK external quality assessment schemes (EQAS) 1980–1988. *Clin Chim Acta* 186:67–82
130. **Hashimoto T, Matsubara F** 1991 The need for primary quality control of commercially available immunoassay kits. *J Clin Pathol* 44:165–167
131. **Smith KA, McConway MG, Perry B, Chapman RS, Beastall GH** 1992 Discrepancies in hFSH measurements by two-site IRMA in the ovulatory phase of the menstrual cycle. *Ann Clin Biochem* 29:351–353
132. **Taylor AE, Khoury RH, Crowley Jr WF** 1994 A comparison of 13 different immunometric assay kits for gonadotropins: implications for clinical investigation. *J Clin Endocrinol Metab* 79:240–247
133. **Heikoop JC, van den Boogaart P, Mulders JWM, Grootenhuis PDJ** 1997 Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins. *Nat Biotech* 15:658–662
134. **Garcia-Campayo V, Sato A, Hirsch B, Sugahara T, Muyan M, Hsueh AJW, Boime I** 1997 Design of stable biologically active recombinant lutropin analogues. *Nat Biotech* 15:663–667
135. **Heikoop JC, van Beuningen-de Vaan MMJ, van den Boogaart P, Grootenhuis PDJ** 1997 Evaluation of subunit truncation and the nature of the spacer for single chain human gonadotrophins. *Eur J Biochem* 245:656–662
136. **Bangham DR** 1989 Aspects by which assays may be characterised. *Scand J Clin Lab Invest* 49 [Suppl 193]:11–19
137. **Ascheim S, Zondek B** 1928 Die Schwangerschaftsdiagnose aus dem Harn durch Nachweis des Hypophysen-vorderlappen-hormons. II. Praktische und theoretische Ergebnisse aus den Harnuntersuchungen. *Klin Woch* 7:1453–1457
138. **Brown PS** 1955 The assay of gonadotrophin from urine of non-pregnant human subjects. *J Endocrinol* 13:59–64
139. **Steelman SL, Pohley FM** 1953 Assay of the follicle stimulating hormone based on the augmentation with chorionic gonadotropin. *Endocrinology* 53:604–616
140. **Mulders JWM, Derksen M, Swolfs A, Maris F** 1997 Prediction of the *in vivo* biological activity of human recombinant follicle stimulating hormone using quantitative isoelectric focusing. *Biologicals* 25:269–281
141. **Reichert Jr LE** 1966 Measurement of luteinizing hormone by the hyperemia and ovarian ascorbic acid depletion assays. *Endocrinology* 78:815–818
142. **Burgon PG, Stanton PG, Robertson DM** 1996 *In vivo* bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms. *Endocrinology* 137:4827–4836
143. **Grasso P, Reichert Jr LE** 1996 *In vivo* effects of follicle stimulating hormone-related synthetic peptides on the mouse estrous cycle. *Endocrinology* 137:5370–5375
144. **Anderson RA, Groome NP, Baird DT** 1998 Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. *Clin Endocrinol (Oxf)* 48:577–584
145. **Storring PL** 1988 The role of biological assays in evaluating purified peptide and protein products. In: *Banbury Report 29: Therapeutic Peptides and Proteins: Assessing the New Technologies*. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 119–134
146. **Campbell RK, Dean-Emig DM, Moyle WR** 1991 Conversion of human chorionic gonadotropin into a follitropin by protein engineering. *Proc Natl Acad Sci USA* 88:760–764
147. **Grossmann M, Szkudlinski MW, Wong R, Dias JA, Ji TH, Weintraub BD** 1997 Substitution of the seatbelt region of the thyroid-stimulating hormone (TSH) β -subunit with the corresponding regions of choriogonadotropin or follitropin confers luteotropic but not follicle stimulating activity to chimeric TSH. *J Biol Chem* 272:15532–15540
148. **Campbell RK, Bergert ER, Wang Y, Morris JC, Moyle WR** 1997 Chimeric proteins can exceed the sum of their parts: implications for evolution and protein design. *Nat Biotech* 15:439–443
149. **Ryle M** 1971 The activity of human follicle stimulating hormone preparations as measured by a response *in vitro*. *J Endocrinol* 51:97–107
150. **Boggis J, Ryle M** 1972 An *in vitro* procedure for the quantitative measurement of follicle stimulating hormone activity. *J Endocrinol* 54:355–356
151. **Rao AJ, Ramachandran J** 1975 Cyclic AMP production in isolated rat seminiferous tubule cell preparations: a potential *in vitro* assay for follicle stimulating hormone. *Life Sci* 17:411–416
152. **Van Damme MP, Robertson DM, Marana R, Ritzen E, Diczfalusy E** 1979 A sensitive and specific *in vitro* bioassay method for the measurement of follicle stimulating hormone activity. *Acta Endocrinol (Copenh)* 91:224–237
153. **Beers WH, Strickland S** 1978 A cell culture assay for follicle stimulating hormone. *J Biol Chem* 253:3877–3881
154. **Gore-Langton R, McKeracher H, Dorrington J** 1980 An alternative

- method for the study of follicle-stimulating hormone effects on aromatase activity in Sertoli cell cultures. *Endocrinology* 107:464–471
155. **Ritzen EM, Froysa B, Gustafsson B, Westerholm G, Diczfalusy E** 1982 Improved *in vitro* bioassay of follitropin. *Horm Res* 16:42–48
 156. **Hsueh AJW, Erickson GF, Papkoff H** 1983 Effects of diverse mammalian gonadotropins on oestrogen and progesterone production by cultured rat granulosa cells. *Arch Biochem Biophys* 225:505–511
 157. **Shah GV, Ritzen EM** 1984 Validation of a bioassay for follitropin in urine samples. *J Endocrinol Invest* 7:59–66
 158. **Jia X-C, Hsueh AJW** 1985 Sensitive *in vitro* assay for the measurement of serum follicle-stimulating hormone. *Neuroendocrinology* 41:445–448
 159. **Jia X-C, Hsueh AJW** 1986 Granulosa cell aromatase bioassay for follicle stimulating hormone: validation and application of the method. *Endocrinology* 119:1570–1577
 160. **Jia X-C, Kessel B, Yen SSC, Tucker EM, Hsueh AJW** 1986 Serum bioactive follicle stimulating hormone during the human menstrual cycle and in hyper- and hypogonadotropic states: application of a sensitive granulosa cell aromatase bioassay. *J Clin Endocrinol Metab* 62:1243–1249
 161. **Guillou F, Martinat N, Combarous Y** 1986 Study of the superactivity of equine follicle-stimulating hormone in *in vitro* stimulation of rat Sertoli cells. *Biochim Biophys Acta* 887:196–203
 162. **Padmanabhan V, Chappel SC, Beitins IZ** 1987 An improved *in vitro* bioassay for follicle stimulating hormone (FSH) suitable for measurement of FSH in unextracted serum. *Endocrinology* 121:1089–1098
 163. **Wang C** 1988 Bioassays for follicle stimulating hormone. *Endocr Rev* 9:374–377
 164. **Simoni M, Nieschlag E** 1991 *In vitro* bioassays of follicle-stimulating hormone: methods and clinical applications. *J Endocrinol Invest* 14:983–997
 165. **Gudermann T, Brockmann H, Simoni M, Gromoll J, Nieschlag E** 1994 *In vitro* bioassay for human serum follicle-stimulating hormone (FSH) based on L cells transfected with a recombinant rat FSH receptor: validation of a model system. *Endocrinology* 135:2204–2213
 166. **Tilly JL, Aihara T, Nishimori K, Jia X-C, Billig H, Kowalski KI, Perlas EA, Hsueh AJW** 1992 Expression of recombinant human follicle-stimulating hormone receptor: species-specific ligand binding, signal transduction, and identification of multiple ovarian messenger ribonucleic acid transcripts. *Endocrinology* 131:799–806
 167. **Christin-Maitre S, Taylor AE, Khoury RH, Hall JE, Martin KA, Smith PC, Albanese C, Jameson JL, Crowley Jr WF, Sluss PM** 1996 Homologous *in vitro* bioassay for follicle-stimulating hormone (FSH) reveals increased FSH biological signal during the mid- to late luteal phase of the human menstrual cycle. *J Clin Endocrinol Metab* 81:2080–2088
 168. **Schiffer Z, Keren-Tal I, Deutsch M, Dantes A, Aharoni D, Weinreb A, Tirosh R, Amsterdam A** 1996 Fourier analysis of differential light scattering for the quantitation of FSH response associated with structural changes in immortalised granulosa cells. *Mol Cell Endocrinol* 118:145–153
 169. **Albanese C, Christin-Maitre S, Sluss PM, Crowley WF, Jameson JL** 1994 Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene. *Mol Cell Endocrinol* 101:211–219
 170. **Joyeux A, Balaguer P, Germain P, Boussioux AM, Pons M, Nicolas JC** 1997 Engineered cell lines as a tool for monitoring biological activity of hormone analogues. *Anal Biochem* 249:119–130
 171. **Simoni M, Jockenhovel F, Nieschlag E** 1994 Polymorphism of human pituitary FSH: analysis of immunoreactivity and *in vitro* bioactivity of different molecular species. *J Endocrinol* 141:359–367
 172. **Burgon PG, Robertson DM, Stanton PG, Hearn MTW** 1993 Immunological activities of highly purified isoforms of human FSH correlate with *in vitro* bioactivities. *J Endocrinol* 139:511–518
 173. **Midgley AR** 1967 Radioimmunoassay for human follicle stimulating hormone. *J Clin Endocrinol Metab* 27:295–299
 174. **Sufi SB, Donaldson A, Jeffcoate SL** 1991 Programme for the provision of matched assay reagents for the radioimmunoassay of hormones in reproductive physiology. In: WHO Special Programme of Research, Development and Training in Human Reproduction, ed. 15. World Health Organization, Geneva
 175. **Chen K-W, Chow S-N, Lee C-YG** 1989 Applications of monoclonal antibodies to human follicle-stimulating hormone in enzyme immunoassays. *Biotechnol Appl Biochem* 11:83–88
 176. **Pettersson K, Ding YQ, Huhtaniemi I** 1992 An immunologically anomalous luteinizing hormone variant in a healthy woman. *J Clin Endocrinol Metab* 74:164–171
 177. **Howanitz JH** 1993 Review of the influence of polypeptide hormone forms on immunoassay results. *Arch Pathol Lab Med* 117:369–372
 178. **Jockenhövel F, Khan SA, Nieschlag E** 1990 Varying dose-response characteristics of different immunoassays and an *in vitro* bioassay for FSH are responsible for changing ratios of biologically active to immunologically active FSH. *J Endocrinol* 127:523–532
 179. **Vakharia DD, Bryant SH, Dias JA** 1992 Topographic analysis of human follicle-stimulating hormone- β using anti-peptide antisera. *Mol Cell Endocrinol* 85:89–97
 180. **Lal D, Mahale SD, Iyer KS** 1996 Studies on the delineation of the hormone-specific antigenic determinants of human follicle-stimulating hormone. *Pept Res* 9:195–202
 181. **Lal D, Mahale SD, Nandedkar TD, Iyer KS** 1997 Identification of bionutralization epitopes of human follicle-stimulating hormone in the regions 31–52 and 66–75 of its β subunit. *J Reprod Immunol* 33:1–14
 182. **Westhoff WE, Slootstra JW, Puijk WC, Kuperus D, Flinterman JF, Schaaper WMM, Oonk HB, Meloen RH** 1996 Detection of epitopes on follicle-stimulating hormone and FSH-antiserum-induced suppression of bioactivity of follicle-stimulating hormone and luteinizing hormone. *J Reprod Immunol* 30:133–149
 183. **Berger P, Panmoung W, Khaschabi D, Mayregger B, Wick G** 1988 Antigenic features of human follicle stimulating hormone delineated by monoclonal antibodies and construction of an immunoradiometric assay. *Endocrinology* 123:2351–2359
 184. **Schwarz S, Berger P, Wick G** 1986 The antigenic surface of human chorionic gonadotropin as mapped by murine monoclonal antibodies. *Endocrinology* 118:189–197
 185. **Nagy A-M, Vanbellinthen A-M, Robyn C, Meuris S** 1996 Epitope mapping on intact, heated and reduced molecular variants of human chorionic gonadotrophin. *Mol Cell Endocrinol* 122:51–57
 186. **Berger P, Bidart JM, Delves PS, Dirnhöfer S, Hoermann R, Isaacs N, Jackson A, Klonisch T, Laphorn A, Lund T, Mann K, Roitt I, Schwarz S, Wick G** 1996 Immunochemical mapping of gonadotropins. *Mol Cell Endocrinol* 125:33–43
 187. **Vakharia DD, Dias JA, Andersen TT** 1991 Determination of subunit contact epitopes of the β -subunit of human follicle-stimulating hormone. *Endocrinology* 128:1797–1804
 188. **Schwarz S, Berger P, Nelboeck E, Khashabi D, Panmoung W, Klieber R, Wick G** 1988 Probing the receptor interaction of glycoprotein hormones with monoclonal antibodies. *J Recept Res* 8:437–453
 189. **Vakharia DD, Dias JA, Thakur AN, Andersen TT, O'Shea A** 1990 Mapping of an assembled epitope of human follicle stimulating hormone β utilising monoclonal antibodies, synthetic peptides and hormone-receptor inhibition. *Endocrinology* 127:658–666
 190. **Weiner RS, Dias JA, Andersen TT** 1991 Epitope mapping of human follicle stimulating hormone α using monoclonal antibody 3A identifies a potential receptor binding sequence. *Endocrinology* 128:1485–1495
 191. **Weiner RS, Andersen TT, Dias JA** 1990 Topographic analysis of the α subunit of human follicle stimulating hormone using site-specific anti-peptide antisera. *Endocrinology* 127:573–579
 192. **Weiner RS, Dias JA** 1992 Identification of assembled epitopes on the α -subunit of human follicle stimulating hormone. *Mol Cell Endocrinol* 85:41–52
 193. **Weiner RS, Dias JA** 1992 Biochemical analysis of proteolytic nicking of the human glycoprotein hormone α -subunit and its effect on conformational epitopes. *Endocrinology* 131:1026–1036
 194. **Niccoli P, Ferrand V, Lejeune P-J, Carayon P** 1996 Interest of epitopic dissection in immunoanalysis of proteins and peptides: review of theoretical and practical aspects. *Eur J Clin Chem Clin Biochem* 34:741–748
 195. **Ferasin L, Gabai G, Beattie J, Bono G, Holder AT** 1997 Enhance-

- ment of FSH bioactivity *in vivo* using site specific antisera. J Endocrinol 152:355-363
196. Westhoff WE, Sloostra JW, Puijk WC, van Leeuwen L, Schaaper WMM, Oonk HB, Meloen RH 1997 *In vitro* inhibition of the biological activity of follicle-stimulating hormone by anti-peptide antisera representing the human follicle-stimulating hormone beta subunit sequence 33-53. Biol Reprod 56:460-468
 197. Schwarz S, Krude H, Klieber R, Dirnhofer S, Lottersberger C, Merz WE, Wick G, Berger P 1991 Number and topography of epitopes of human chorionic gonadotropin (hCG) are shared by desialylated and deglycosylated hCG. Mol Cell Endocrinol 80:33-40
 198. Krichevsky A, Birken S, O'Connor J, Acevedo HF, Bikel K, Lustbader J, Hartree A, Canfield RE 1994 Development, characterisation and application of monoclonal antibodies to the native and synthetic β COOH-terminal portion of human chorionic gonadotropin (hCG) that distinguish between the native and desialylated forms of hCG. Endocrinology 134:1139-1145
 199. Birken S, Agosto G, Amr S, Nisula B, Cole L, Lewis J, Canfield R 1988 Characterisation of antisera distinguishing carbohydrate structures in the β -carboxyl-terminal region of human chorionic gonadotropin. Endocrinology 122:2054-2063
 200. Jiang LG, Sairam MR 1994 Topographical differences in human choriongonadotropin antagonist as revealed by monoclonal antibodies. Mol Cell Endocrinol 99:201-210
 201. Chen W, Bahl OP 1992 Polyclonal antibodies against the polypeptide and carbohydrate epitopes of recombinant human choriongonadotropin β -subunit. Mol Cell Endocrinol 86:57-66
 202. Ohbayashi H, Endo T, Yamashita K, Kuroki M, Matsuoka Y, Kobata A 1989 Novel methods to determine the epitopes on the asparagine-linked oligosaccharides of glycoproteins. Anal Biochem 182:200-206
 203. Rafferty B, Mower JA, Ward HL, Rose M 1995 Differences in carbohydrate composition of FSH preparations detected with lectin-ELISA systems. J Endocrinol 145:527-533
 204. Papandreou MJ, Asteria C, Pettersson K, Ronin C, Beck-Peccoz P 1993 Concanavalin A affinity chromatography of human serum gonadotropins: evidence for changes of carbohydrate structure in different clinical conditions. J Clin Endocrinol Metab 76:1008-1013
 205. Reichert Jr LE, Ramsey RB, Carter EB 1975 Application of a tissue receptor assay to measurement of serum follitropin (FSH). J Clin Endocrinol Metab 41:634-637
 206. Cheng K-W 1975 A radioreceptor assay for follicle stimulating hormone. J Clin Endocrinol Metab 41:581-589
 207. Minegishi T, Igarashi M, Wakabayashi K 1980 Measurement of rat serum FSH by radioreceptor assay and comparison with radioimmunoassay. Endocrinol Jpn 27:717-725
 208. Schneyer AL, Sluss PM, Whitcomb RW, Hall JE, Crowley Jr WF, Freeman RG 1991 Development of a radioligand receptor assay for measuring follitropin in serum: application to premature ovarian failure. Clin Chem 37:508-514
 209. Valove FM, Finch C, Anasti JN, Froehlich J, Flack MR 1994 Receptor binding and signal transduction are dissociable functions requiring different sites on follicle stimulating hormone. Endocrinology 135:2657-2661
 210. Moyle WR, Anderson DM, Macdonald GJ, Armstrong EG 1988 Bioimmunoassay (BIA): a sandwich immunoassay scheme employing monoclonal antibodies and hormone receptors to quantify analytes. J Recept Res 8:419-436
 211. Dahl KD, Bicsak TA, Hsueh AJW 1988 Naturally occurring antihormones: secretion of FSH antagonists by women treated with a GnRH analog. Science 239:72-74
 212. Sebok K, De Léan A, Sairam MR 1987 Analysis of the kinetics of ovine follitropin agonist-antagonist interactions with pig ovarian membranes. J Biochem 26:3650-3658
 213. Lee DW, Butler WJ, Horvath PM, Shelden RM, Reichert Jr LE 1991 Human follicular fluid contains a follicle-stimulating hormone (FSH) receptor binding inhibitor which has FSH agonist activity, is immunologically similar to FSH, but can be distinguished from FSH. J Clin Endocrinol Metab 72:1102-1107
 214. DiZerega GS, Marrs RP, Roche PC, Campeau JD, Kling OR 1983 Identification of proteins in pooled human follicular fluid which suppress follicular response to gonadotropins J Clin Endocrinol Metab 56:35-41
 215. Wide L 1981 Electrophoretic and gel chromatographic analyses of follicle stimulating hormone in human serum. Ups J Med Sci 86: 249-258
 216. Ulloa-Aguirre A, Espinoza R, Damian-Matsumura P, Chappel SC 1988 Immunological and biological potencies of the different molecular species of gonadotrophins. Hum Reprod 3:491-501
 217. Weissshaar G, Hiyama J, Renwick AGC 1991 Site-specific N-glycosylation of human chorionic gonadotrophin - structural analysis of glycopeptides by one- and two-dimensional ^1H NMR spectroscopy. Glycobiology 1:393-404
 218. De Beer T, Van Zuylen CWEM, Leeflang BR, Hard K, Boelens R, Kaptein R, Kamerling JP, Vliegthart JFG 1996 NMR Studies of the free α subunit of human chorionic gonadotrophin. Structural influences of n-glycosylation and the β subunit on the conformation of the α subunit. Eur J Biochem 241:229-242
 219. Laidler P, Cowan DA, Hider RC, Keane A, Kicman AT 1995 Tryptic mapping of human chorionic gonadotropin by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 9:1021-1026
 220. Liu C-L, Bowers LD 1996 Immunoaffinity trapping of urinary chorionic gonadotrophin and its high-performance liquid chromatographic-mass spectrometric confirmation. J Chromatogr B Biomed Appl 687:213-220
 221. Liu C-L, Bowers LD 1997 Mass spectrometric characterization of the β -subunit of human chorionic gonadotrophin. J Mass Spectrom 32:33-42
 222. Hermentin P, Witzel R, Kanzy E-J, Diderrich G, Hoffmann D, Metzner H, Vorlop J, Haupt H 1996 The hypothetical N-glycan charge: a number that characterises protein glycosylation. Glycobiology 6:217-230
 223. Hard K, Mekking A, Damm JBL, Kamerling JP, De Boer W, Wijnands RA, Vliegthart JFG 1990 Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. Eur J Biochem 193:263-271
 224. Amoresano A, Siciliano R, Orru S, Napoleoni R, Altarocca V, De Luca E, Sirna A, Pucci P 1996 Structural characterisation of human recombinant glyco hormones follitropin, lutropin and choriogonadotropin expressed in Chinese hamster ovary cells. Eur J Biochem 242:608-618
 225. Harris SD, Anobile CJ, McLoughlin JD, Mitchell R, Lambert A, Robertson WR 1996 Internal carbohydrate complexity of the oligosaccharide chains of recombinant human follicle stimulating hormone (Puregon, Org 32489): a comparison with Metrodin and Metrodin -HP. Mol Hum Reprod 2:807-811
 226. Bishop LA, Nguyen TV, Schofield PR 1995 Both of the β -subunit carbohydrate residues of follicle-stimulating hormone determine the metabolic clearance rate and *in vivo* potency. Endocrinology 136:2635-2640
 227. Robertson DR 1991 Circulating half-lives of follicle stimulating hormones and luteinizing hormone in pituitary extracts and isoform fractions of ovariectomized and intact ewes. Endocrinology 129:1805-1813
 228. Storrington PL, Khan SA, Mistry YG, Diczfaluzy E 1988 Plasma clearance in the rat of the LH bioactivity of two human LH standards of differing molecular composition. J Endocrinol 119:327-334
 229. Chappel SC 1993 Ovulation kit comprising isoforms with varying half-lives. US Patent Number 5,262,518
 230. Reddi K, Wickings EJ, McNeilly AS, Baird DT, Hillier SG 1990 Circulating bioactive follicle stimulating hormone and immunoreactive inhibin levels during the normal human menstrual cycle. Clin Endocrinol (Oxf) 33:547-557
 231. Chappel SC, Ulloa-Aguirre A, Coutifaris C 1983 Biosynthesis and secretion of follicle stimulating hormone. Endocr Rev 4:179-211
 232. Storrington PL 1992 Assaying glycoprotein hormones - the influence of glycosylation on immunoreactivity. TIBTECH 10:427-432
 233. Dahl KD, Stone MP 1992 FSH isoforms, radioimmunoassays, bioassays, and their significance. J Androl 13:11-22
 234. Van Wezenbeek P, Draaijer J, Van Meel F, Olijee W 1990 Recombinant follicle stimulating hormone. I. Construction, selection and characterisation of a cell line. In: Crommelin DJA, Schellekens

- H (eds) From Clone to Clinic. Kluwer Academic Publishers, The Netherlands, pp 245–251
235. **De Boer W, Mannaerts B** 1990 Recombinant human follicle stimulating hormone. II. Biochemical and Biological Characteristics. In: Crommelin DJA, Schellekens H (eds) From Clone to Clinic. Kluwer Academic Publishers, The Netherlands, pp 253–259
 236. **Siebold B** 1996 Physicochemical characterisation of recombinant human follicle stimulating hormone. *Hum Reprod* 11[Suppl]:1109–115
 237. **Galway AB, Hsueh AJW, Keene JL, Yamoto M, Fauser BCJM, Boime I** 1990 *In vitro* and *in vivo* bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. *Endocrinology* 127: 93–100
 238. **Mannaerts B, De Leeuw R, Geelen J, Van Ravestein A, Van Wezenbeek P, Schuurs A, Kloosterboer H** 1991 Comparative *in vitro* and *in vivo* studies on the biological characteristics of recombinant human follicle stimulating hormone. *Endocrinology* 129: 2623–2630
 239. **Flack MR, Bennet AP, Froehlich J, Anasti JN, Nisula BC** 1994 Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line. *J Clin Endocrinol Metab* 79:756–760
 240. **Lambert A, Rodgers M, Mitchell R, Wood AM, Wardle C, Hilton B, Robertson WR** 1995 *In-vitro* biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. *Hum Reprod* 10:1928–1935
 241. **Biffoni M, Cantelmo A, Marcucci I, Martelli F, Suzuki H, Borrelli F, Suzuki K** 1994 General pharmacology studies on recombinant human follicle stimulating hormone. *Arzneimittelforschung Drug Res* 44:1096–1102
 242. **Porchet HC, Le Cotonnec J-Y, Canali S, Zanolo G** 1993 Pharmacokinetics of recombinant human follicle stimulating hormone after intravenous, intramuscular and subcutaneous administration in monkeys, and comparison with intravenous administration of urinary follicle stimulating hormone. *Drug Metab Dispos* 21:144–150
 243. **Weinbauer GF, Simoni M, Hutchison JS, Nieschlag E** 1994 Pharmacokinetics and pharmacodynamics of recombinant and urinary human FSH in the male monkey (*Macaca fascicularis*). *J Endocrinol* 141:113–121
 244. **Le Cotonnec J, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M** 1994 Clinical Pharmacology of recombinant human follicle stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. *Fertil Steril* 61:669–678
 245. **Le Cotonnec J, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M** 1994 Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. *Fertil Steril* 61:679–686
 246. **Porchet HC, Le Cotonnec J, Loumaye E** 1994 Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. *Fertil Steril* 61:687–695
 247. **Mannaerts B, Shoham Z, Schoot D, Bouchard P, Harlin J, Fauser B, Jacobs H, Rombout F, Coelingh Bennink H** 1993 Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle stimulating hormone (Org 32489) in gonadotropin deficient volunteers. *Fertil Steril* 59:108–114
 248. **Fisch B, Avrech OM, Pinkas H, Neri A, Rufas O, Ovadia J, Loumaye E** 1995 Superovulation before IVF by recombinant *vs.* urinary human FSH (combined with a long GnRH analogue protocol): a comparative study. *J Assist Reprod Genet* 12:26–31
 249. **Out HJ, Mannaerts BM, Driessen SGAJ, Coelingh Bennink HJT** 1996 Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies. *Hum Reprod Update* 2:162–171
 250. **Vitt UA, Kloosterboer HJ, Rose UM, Mulders JW, Kiesel PS, Bete S, Nayudu PL** 1998 Isoforms of human recombinant follicle-stimulating hormone: comparison of effects on murine follicle development *in vitro*. *Biol Reprod* 59:854–861
 251. **Pettersson KS, Soderholm JR** 1991 Individual differences in lutropin immunoreactivity revealed by monoclonal antibodies. *Clin Chem* 37:333–340
 252. **Demers LM** 1991 Monoclonal antibodies to lutropin: are our immunoassays too specific? *Clin Chem* 37:311–312
 253. **Layman LC, Lee EJ, Peak DB, Namnoum AB, Vu KV, van Lingen BL, Gray MR, McDonough PG, Reindollar RH, Jameson JL** 1997 Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone β subunit gene. *N Engl J Med* 337: 607–611
 254. **Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeschini G, Benedetti A, Chatterjee VK** 1993 Primary amenorrhoea and infertility due to a mutation in the β -subunit of follicle stimulating hormone. *Nat Genet* 5:83–86
 255. **Huhtaniemi I, Pettersson K** 1998 Mutations and polymorphisms in the gonadotrophin genes; clinical relevance. *Clin Endocrinol (Oxf)* 48:675–682
 256. **Conway GS** 1996 Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. *Clin Endocrinol (Oxf)* 45: 657–663
 257. **Themmen AP, Martens JW, Brunner HG** 1997 Gonadotropin receptor mutations. *J Endocrinol* 153:179–183
 258. **Simoni M, Gromoll J, Nieschlag E** 1997 The follicle stimulating hormone receptor: biochemistry, molecular biology, physiology and pathophysiology. *Endocr Rev* 18:739–773
 259. **Chappel SC** 1990 Editorial: Biological to immunological ratios. *J Clin Endocrinol Metab* 70:1494–1495

27th European Symposium on Calcified Tissues
May 6–10, 2000
Tampere, Finland

These themes and others will be discussed: Osteoblasts, Osteoclasts, Bone matrix, Signal transduction, Mechanotransduction, Growth factors and cytokines, Calcitropic hormones, Estrogens and SERMS. Diagnostics: Bone mineral density, Ultrasound, Biochemical markers of bone metabolism, etc., Osteoporosis: Epidemiology, Pathophysiology, Diagnosis, Treatment, Metabolic bone diseases, Cancer and bone, Genetics of skeletal disorders.

Further information: www.congcreator.com/ects-2000, Fax: 358-9-4542-1930,
 E-mail: ects2000@congcreator.com